

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 166 799 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**02.01.2002 Bulletin 2002/01**

(51) Int Cl.7: **A61K 45/06**

(21) Application number: **00250214.4**

(22) Date of filing: **28.06.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

- **Haberey, Martin, Dr.**  
**12169 Berlin (DE)**
- **Thierauch, Karl-Heinz, Dr.**  
**14169 Berlin (DE)**

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**  
**13342 Berlin (DE)**

(72) Inventors:  
• **Siemeister, Gerhard**  
**13503 Berlin (DE)**

Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

(54) **Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)**

(57) The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF

receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**EP 1 166 799 A1**

## Description

[0001] The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

[0002] Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

[0003] The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442, 1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al., Nature 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

[0004] The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., Cell 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

[0005] The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al., Lab. Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al., Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

[0006] In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine

kinase (Fong et al., *Cancer Res.* 59, 99-106, 1999; Wedge et al., *Cancer Res.* 60, 970-975, 2000; Wood et al. *Cancer Res.* 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., *Cancer Res.* 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., *Cancer Res.* 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., *J. Clin. Invest.* 103, 159-165, 1999).

**[0007]** The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kai-painen et al., *Cancer Res.* 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., *Br. J. Cancer* 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., *Cancer Res.* 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., *Cancer Res.* 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., *Am. J. Pathol.* 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., *Science* 284, 1994-1998, 1999; Holash et al., *Oncogene* 18, 5356-5362, 1999).

**[0008]** Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., *J. Clin. Invest.* 103, 159-165, 1999; Lin et al. *Proc. Natl. Acad. Sci. USA* 95, 8829-8834, 1998; Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., *Nature* 367, 576-579, 1994; Kim et al., *Nature* 362, 841-844, 1993; Millauer et al., *Cancer Res.* 56, 1615-1620, 1996; Goldman et al., *Proc. Natl. Acad. Sci. USA* 95, 8795-8800, 1998; Fong et al., *Cancer Res.* 59, 99-106, 1999; Wedge et al., *Cancer Res.* 60, 970-975, 2000; Wood et al. *Cancer Res.* 60, 2178-2189, 2000; Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., *Nature* 362, 841-844, 1993; Wood et al. *Cancer Res.* 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., *J. Clin. Invest.* 103, 159-165, 1999; Lin et al., *Proc. Natl. Acad. Sci. USA* 95, 8829-8834, 1998; Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999).

**[0009]** However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

**[0010]** Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

**[0011]** Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic

agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

- 5 (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

15 **[0012]** A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am. 20 Associ. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Associ. Cancer Res., San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is 25 prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as Pseudomonas exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), Cancer 30 Res. 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or 35 receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described.

**[0013]** Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

40 **[0014]** Examples for delivery-/Targeting-Systems have been described as ligand/ antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothelial cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci., U.S.A.94, 8795-8800, and as endothelial cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).


**[0015]** Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I

45

50


55






in which

- 20
- $r$  has the meaning of 0 to 2,
- $n$  has the meaning of 0 to 2;
- $R_3$  und  $R_4$  a) each independently from each other have the meaning of lower alkyl,
- 25 b) together form a bridge of general partial formula II,



- 40
- $m$  wherein the binding is via the two terminal C- atoms, and
- has the meaning of 0 to 4; or
- c) together form a bridge of partial formula III



- 50
- 55
- $G$  wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$  ;
- has the meaning of  $C_1-C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3-C_6$ - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2$ , oxa (-O-), thia (-S-) or imino (-NH-),
- A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than


three of these Substituents have the meaning of N,  
 Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
 R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or lower alkyl,  
 X has the meaning of imino, oxa or thia;  
 5 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and  
 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygene atom, or a salt thereof.

[0016] A preferred salt is the salt of an organic acid, especially a succinate.

[0017] These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0018] Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example

anthranil acid derivatives of general formula IV




in which


A has the meaning of group =NR<sup>2</sup>,

W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR<sup>8</sup>,

Z has the meaning of the group =NR<sup>10</sup> or =N-, -N(R<sup>10</sup>)-(CH<sub>2</sub>)<sub>q</sub>-, branched or unbranched C<sub>1-6</sub>-Alkyl or is the group



or A, Z and R<sup>1</sup> together form the group



- 20 m, n and o has the meaning of 0 - 3,  
 q has the meaning of 1 - 6,  
 R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub> independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>,  
 and/ or R<sub>a</sub> and/ or R<sub>b</sub> together with R<sub>c</sub> and or R<sub>d</sub> or R<sub>c</sub> together with R<sub>e</sub> and/ or R<sub>f</sub> form a  
 bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,  
 25 X has the meaning of group =NR<sup>9</sup> or =N-,  
 Y has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,  
 P has the meaning of integer 1-4,  
 R<sup>1</sup> has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-  
 alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen,  
 or is unsubstituted or substituted aryl or heteroaryl,  
 30 R<sup>2</sup> has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or form a bridge with up to 3 ring atoms with R<sub>a</sub>-  
 R<sub>f</sub> together with Z or R<sub>1</sub>,  
 R<sup>3</sup> has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally  
 substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,  
 35 R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> independently from each other have the meaning of hydrogen, halogen or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-  
 alkyl or C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more  
 of halogen, or R<sup>5</sup> and R<sup>6</sup> together form the group



- 45 R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their  
 isomers and salts.

[0019] These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical com-  
 position.


[0020] More preferentially compounds of geneareal formula V

50

55

5

10




V,

15

in which


R¹ has the meaning of group

20



25


30



35

in which R⁵ is chloro, bromo or the group -OCH₃,

40




45

in which R⁷ is -CH₃ or chloro,

50

55




in which R<sup>8</sup> is -CH<sub>3</sub>, fluoro, chloro or -CF<sub>3</sub>

in which R<sup>4</sup> is fluoro, chloro, bromo, -CF<sub>3</sub>, -N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or -CH<sub>2</sub>OH

in which R<sup>6</sup> is -CH<sub>3</sub> or chloro

R<sup>2</sup> has the meaning of pyridyl or the group



and  
R<sup>3</sup> has the meaning of hydrogen or fluoro, as well as their

isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

**[0021]** A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

**[0022]** Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

[0023] For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately.

[0024] The inventive compositions comprise as compound I or as compound II at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

[0025] Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59. Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

[0026] Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

[0027] The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

[0028] The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

[0029] Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum,

plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/or buffer.

5 These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds  
**[0030]** For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

10 For oral application especially suitable are tablets, pills or capsules with talcum and/or hydrocarbon carriers or binders, such as lactose, maize or potato starch.

**[0031]** The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener. The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

15 The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

**[0032]** These formulations and application forms are also part of the instant invention.

**[0033]** Combined functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

25 **[0034]** The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.

**[0035]** VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor tyrosine kinases Tie1 and Tie2.

**[0036]** Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of the present invention can be applied orally, parenterally, or via gene therapeutic methods.

35 **[0037]** Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

40 **[0038]** The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

#### 45 **Example 1**

**[0039]** Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

50 **[0040]** Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss nu/nu mice were s.c. injected with  $1 \times 10^6$  transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0041] Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm<sup>2</sup> to 38 days. This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

## Example 2

[0042] Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

[0043] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0044] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by



means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

[0045] The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

### Example 3

[0046] Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0047] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0048] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

### Example 4

[0049] Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0050] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing

the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

**[0051]** Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm<sup>3</sup> within 28 days. **[0052]** The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

#### Example 5

**[0053]** Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

**[0054]** Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0055] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

#### Example 6

[0056] Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

[0057] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0058] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylme-

thyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm<sup>3</sup> within 28 days.

[0059] The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

#### Description of the figures

[0060] Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

mock, con.	=	treatment group 1
mock+VEGF-A	=	treatment group 2
sTIE2-cl13	=	treatment group 3
sTIE2-cl13+VEGF-A	=	treatment group 4

[0061] Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

[0062] Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

[0063] Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

[0064] Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

[0065] Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

## Annex to the application documents - subsequently filed sequences listing

[0066]

5

Sequence Identifier

10

&lt;110&gt; Schering Aktiengesellschaft

&lt;120&gt; Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

&lt;130&gt; 51867AEPM1XX00-P

15

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 59

20

&lt;210&gt; 1

&lt;211&gt; 1835

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 1

25

```

ttttacagtt ttccttttct tcagagttaa ttttgaatrt tcatttttgg ataaccaagc 60
agctctttaa gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaaaaaac cataatggtg ccacagggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420
aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaaacca acaacaacaa aaagcgaggg actgtctggt gtcactgtca aaaaggcact 540
tggagttaaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcgga cagatgaaca caaaggaaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaaacgca acctaacca agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagtctctca cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cggttttctta atgtccctgg tggcggatac 1020
gccgagtcct cggagggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcccttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtccacagg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcatagc tcatttaatg ttaaacgccca tcaggggcct ctctctccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgagtcctg tctggctcgc tctctctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtcccac attcgcctac actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggctctttc tgctgggtgct 1620
cttgacggg cggttagttc tgctgcagag acaaaagcatc tcccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttctctc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

```

55

&lt;210&gt; 2

&lt;211&gt; 581

&lt;212&gt; DNA

&lt;213&gt; Human

# EP 1 166 799 A1

<400> 2

gttctagatt gttttattca gtaattagct cttaagaccc ctggggcctg tcttaccag 60  
acactaacia cagtcctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120  
5 tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgctgttg 180  
agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240  
tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360  
agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420  
aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtggt gtgcgtatga 480  
10 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540  
cacctcccca tgacatcctc catgagcctc ctgatgtagt g

<210> 3

<211> 516

<212> DNA

<213> Human

<400> 3

tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60  
20 tcagcccaga catgtgcac tacatcacag agcacatgct catgtcgagg aacctgaatg 120  
gacactctgg gttgatgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180  
ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240  
agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
tcctgcgcat tgcaggctct tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360  
atgaactgga tgagggaagg ctctattgca acagttgctt ggcccagcag tgcataca 420  
25 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480  
atgaagttcc agagtttgtt gtgtaaagt cgtctg

<210> 4

<211> 1099

<212> DNA

<213> Human

<400> 4

cccacaacac agggggcctg aaacacgcca gcctctctc tgtggtcagc ttggcccagt 60  
cctgtcact ggatcacagc ccattgtagg tggggcatgg tggggatcag gggccctggc 120  
35 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccttgggtcg 180  
ggggtgcgct ttggccttgc cgtgcccctc tccccgggt gaggcagcga cacagcagg 240  
gcaccaactc cagcagggtta agcaccagg agatgagtc aaccaccaac atgaagatga 300  
tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcagggtg 360  
ctcgtcgcca cacaacacag ggctccatgg tccagccgta caggcgccac tggccataga 420  
ggaagcctgc ctctagcaca ctcttgacga gcacactggc gacatagggt cccatcagt 480  
40 ctccgcggat cgccagggca ccatcttctg ccaccgagat cttggccatc tgacgctcta 540  
cgccgcgag cgcccgctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600  
ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660  
gggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtg gagatgggga 720  
aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780  
actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaaagatga 840  
45 agagcaccgt cagccagatc ttaccacca cggtcgagtg ctctggacc tggccagca 900  
acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcgcca aggagacaga 960  
gcacgtcagt gtgtcagcat ggcaccttc tggctcgccc agcaacaagc ctgcaggag 1020  
gtctgccacg cccgttctac cgctgctg ccggcgggcc cagggtggag tggggacgat 1080  
ggccggagtg acgcccgcg

<210> 5

<211> 1015

<212> DNA

<213> Human

<400> 5

gaggataggg agcctgggggt caggagtggt ggagacacag cgagactctg tctccaaaaa 60

EP 1 166 799 A1

5  
10  
15

aaaaagtgt	ttttgaaat	gttgaggtg	aaatgatgg	aaccaacatt	ctttggattt	120
agtggggagc	ataatagcaa	acacccccct	ggttcgcaca	tgtacaggaa	tgggacccag	180
ttggggcaca	gccatggact	tccccgccct	ggaatgtgtg	gtgcaaagt	ggggcagggc	240
ccagacccaa	gaggagaggg	tggtccgcag	acacccccgg	atgtcagcat	cccccgacct	300
gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
gtatatgctg	ggaacagggt	gcaggggcca	agcgttcctc	cttcagcctt	gacttggggc	420
atgcaccccc	tctcccccaa	acacaaacaa	gcacttctcc	agtatggtgc	caggacaggt	480
gtcccttcag	tcctctggtt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
gtttgtaacct	ctgcgtcctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
atcatcattg	ttgctttatc	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
aatgtgcttc	cctccctggg	gtctcacacg	ctcccacgag	aatgccacag	gggcccgtgca	720
ctgggcaggc	ttctctgtag	aacccccagg	gcttcggccc	agaccacagc	gtcttgccct	780
gagcctgagc	caggaggtcc	cgaaacttctg	cattcacaga	ccacctccac	aattgttata	840
accaaaggcc	tcctgttctg	ttatttcact	taaatcaaca	tgctattttg	ttttcactca	900
cttctgactt	tagcctcgtg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	

<210> 6  
<211> 2313  
<212> DNA  
<213> Human

20

<400> 6

25

30

35

40

45

50

55

ccagagcagg	cctggtggtg	agcagggacg	gtgcaccgga	cggcggggatc	gagcaaatgg	60
gtctggccat	ggagcacgga	gggtcctacg	ctcgggcggg	gggcagctct	cggggctgct	120
ggtattacct	gcgctacttc	ttcctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
ggctcgtgct	cttcatggtc	tatggcaacg	tgcacgtgag	cacagagtcc	aacctgcagg	240
ccacctgagc	ccgagccgag	ggcctataca	gtcagctcct	agggctcagc	gcctcccgag	300
ccaacttgac	caaggagctc	aacttcacca	cccgcgcaa	ggatgccatc	atgcagatgt	360
ggctgaatgc	tgcgcccgac	ctggaccgca	tcaatgccag	cttcgccccag	tgccagggtg	420
accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgccttgctc	ttcatgctga	540
atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgcactaagg	600
ataaggaaa	cgtgctgctg	aacaaacgcg	tggcggagga	acagctgggt	gaatgcgtga	660
aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaagggtga	720
agccctctgc	gcgccctggg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
ctcgggaattg	gcctccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
gggtggaggag	ctggcccggg	gcctccgggg	ggatatcgaa	cgcgtggccc	gcgagaactc	960
agacctccaa	cgccagaagc	tggaaagcca	caggggectg	cgggccagtc	aggaggcgaa	1020
acagaaggtg	gagaaggagg	ctcaggcccg	ggaggccaag	ctccaagctg	aatgctcccg	1080
gcagacccag	ctagcgcctg	aggagaaggc	ggtgctgcgg	aaggaaacgag	acaacctggc	1140
caaggagctg	gaagagaaga	agagggaggc	ggagcagctc	aggatggagc	tggccatcag	1200
aaactcagcc	ctggacacct	gcatcaagac	caagtgcgag	ccgatgatgc	cagtgtcaag	1260
gcccattggg	cctgtcccca	acccccagcc	catcgaccca	gctagcctgg	aggagttcaa	1320
gaggaagatc	ctggagctcc	agaggccccc	tgcaggcatc	cctgtagccc	catccagtgc	1380
ctgaggaggc	tccaggccctg	aggaccaagg	gatggcccga	ctcggcggtt	tgcggaggat	1440
gcagggatat	gctcacagcg	cccgacacaa	ccccctcccg	ccgcccccaa	ccacctaggg	1500
ccaccatcag	acaactccct	gcatgcaaac	ccctagtacc	ctctcacacc	cgcaccccg	1560
cctcacgatc	cctcacccag	agcacacggc	cgcggagatg	acgtcacgca	agcaacggcg	1620
ctgacgtcac	atatcaccgt	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
tcacacagac	gcggcgatgg	catcacacag	acggtgatga	tgtcacacac	agacacagtg	1860
acaacacaca	ccatgacaac	gacacctata	gatatggcac	caacatcaca	tgcacgcattg	1920
ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgacctggc	1980
acacggggcca	aggtacccac	aggatcccat	ccccctccgc	acagccctgg	gccccagcac	2040
ctccctccct	cagcttctct	ggcctcccag	ccacttctct	acccccagtg	cctggaccgc	2100
gaggtgagaa	caggaagcca	ttcacctccg	ctccttgagc	gtgagtgttt	ccaggacccc	2160
ctcggggccc	tgagccgggg	gtgagggtca	cctgttgtcg	ggaggggagc	cactccttct	2220
ccccaaactc	ccagccctgc	ctgtggcccg	ttgaaatgtt	ggtggcactt	aataaatatt	2280
agtaaatcct	taaaaaaaaa	aaaaaaaaaa	aaa			

<210> 7  
<211> 389

EP 1 166 799 A1

<212> DNA  
<213> Human

<400> 7

5

gccaaaaaga tggccttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60  
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120  
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180  
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240  
10 tgacctttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300  
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360  
tccttttctg gtgtccagtg ggtaacatc

<210> 8  
<211> 157  
<212> DNA  
15 <213> Human

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60  
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120  
cctcaatctg tgaactatat gtgagtttga taatttg

<210> 9  
<211> 561  
<212> DNA  
25 <213> Human

<400> 9

30

aatagtcaaa acataaaca aagctaatta actggcactg ttgtcacctg agactaagtg 60  
gatgttggtg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120  
tgaactgaac tattctgtta catatggttg acaaatctgt gtgttatctt ttttctacct 180  
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttoga tgatgaacat 240  
tcctgatttt ttgcctgatt aaatctctgtt gagctctact tgtggtcatt caagatttta 300  
tgatgttgaa aggaaaaagt aaatgacct ttaaaaattg tattttgggt gatgatagtc 360  
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420  
ttaaacctat aatgagtatt ctaaatggag aattcttaat ggatggatta tcccctgatc 480  
35 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540  
ctgcccacat ttctaggaaa a

<210> 10  
<211> 1508  
<212> DNA  
40 <213> Human

<400> 10

45

gacaaacacg agagactcca cggctctgct gagcaccgcc agcctcctag gctccagcac 60  
tcgcagggtc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120  
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180  
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactc 240  
gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300  
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctaccgaag gcctctgcca 360  
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420  
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480  
tgtgtgtgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540  
50 ggtgtcatgt cccctctttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600  
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgcccgtg taaaaactca 660  
aacacagttt gctgcaaagt tcccactgtc ccccttagga actttgaaaa accaactatg 720  
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780  
atgcaaccaa ctaaacagtt ataacttttg cactgttaat agaaagtgtg gatagtcttt 840  
60 gctgttttgc gtgaaatgct ttttgtccat gtgcccgttt aactgatag ctgtttagaa 900  
55 ctcagctaat ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960  
ctaagcaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaact 1020



EP 1 166 799 A1

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

tgtaaatag cagatgactt ttttccattg ttttccag agagaatgtg ctatatTTTT 1080  
gtatatataa taatatTTgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140  
cacaaaatat tatactaata tgttgtacat tccgaagaat gtgaatcaat cagtatgttt 1200  
ttagattgta ttttgcccta cagaaagcct ttattgtaag actctgattt ccctttggac 1260  
ttcatgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320  
attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaatatTTa 1380  
ttttaagagg catcttacia aTTTTGccc ttttatgagg atgtgatagt tgctgcaaT 1440  
gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500  
aaaaaaa

<210> 11  
<211> 389  
<212> DNA  
<213> Human

<400> 11

gggcagggtga tcagggcaca catttcccgT ccattgagac agtagcattc ccggcaccca 60  
tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccgcac 120  
aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180  
ctgtcctgct ggaaacccae ggggcagatc ttactgcatg agagctctgg acatttctta 240  
cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300  
cagattatgg gtcctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360  
acctcggccg cgaccacgct gggtaccga

<210> 12  
<211> 981  
<212> DNA  
<213> Human

<400> 12

tttttttttt ttggattgca aaaattttatt aaaattggag acaactgtttt aatcttcttg 60  
tgccatgaga ctccatcagg cagtctacia agaccactgg gaggcTgagg atcacttgag 120  
cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180  
aagacccttt caagcagtaa gctgcatgct tgcttggtgt ggtcattaaa aaccctagtt 240  
taggataaca acatattaat cagggcaaaa taaaaatgtg tgatgcttgt tagtagagta 300  
acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360  
cattacatca ttggttacac tgaaaaatcat cacatgtacc aaaagctgac tcacctagtt 420  
taggataaca ggtctgcctg tttgaagatg aaaaaataaT cccatttaaa atttgccta 480  
ctcaattttc ttctcagTca cattttaact tttaaacagc taatcactcc catctacaga 540  
ttaagggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagtttaaa 600  
ctaattgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660  
cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720  
taccaggagc agaaccatta agctggTcca ggcaagttgg actccaccat ttcaacttcc 780  
agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840  
agtagctatt ctcatccttc cttggggaca caactgtcca taagtgcta tccagagcca 900  
actgcatct gcaccagca ccatacctca caggagtcca ctcccacgag ccgctgtgat 960  
ataagagttc ttttgatgac g

<210> 13  
<211> 401  
<212> DNA  
<213> Human

<400> 13

ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60  
aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120  
tctctccccc agagcgaccc cccgggcagg tccggggcca aggaatgacc cagcaactgc 180  
tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240  
gtggTcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300  
tggaagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360  
acttcagcat atttagttgt cattaaaatt aagctgatat t

<210> 14

# EP 1 166 799 A1

<211> 1002  
<212> DNA  
<213> Human

5

<400> 14

10

15

20

```
gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
tttggaaaatg ttaaatacaaa gtccatttct ctttgtccag ctgggttttag cttagaggtag 180
ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaataa tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcac ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttcccccactt ttttaagtag gcttagcttt gagtgatttt 420
tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatggtgcca tatgtcccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat cttttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
attcaataaa cattagccaa gctaattgtc caagccactg tgccagggtat taacaatata 780
acaacaataa aagacacagt ccttcctctc aaggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaatctct 900
gcctatgttc tcagatatcc tgggttaggtc aggagtggga acccaaaatc aattctttta 960
acaaacacta aaggtgattc taacacaggc ggtgtgagga cc
```

<210> 15  
<211> 280  
<212> DNA  
<213> Human

25

<400> 15

30

```
cgagggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat tatcctattt 60
ataatatccc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
aactgtatta tgactctcaa tttttaaaca ttttaaaaaa tgttagtggt tgtaaagcac 240
caatcttaac tatctcacct gcccgggcgg ccgctcgagg
```

<210> 16  
<211> 2041  
<212> DNA  
<213> Human

35

<400> 16

40

45

50

55

```
ccccccgcag aactccccc tgggaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt taaaaaacia gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtagata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
ataaaaacia gcactgagtg tgttctcttg aagtaaaagg gtctaataaa aaataaaaga 660
tagatatttg ttatagtctg acatttttaac agtcatagta tttagacgtt cgtgaccagt 720
gcattttgga ctctctcagg atcaaaaatac gagtctgcca actgtattaa atcctcctcc 780
acccctccca ccagttgggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggt tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataaagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
gtaaatgact ctgggaggtat gctaattgcca gagcctcaga ctgggtggac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320
```

EP 1 166 799 A1

5 taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagcct 1380  
 catcagtcctc tgaaggcttc aattttttag caaggttctc actaagatca gtgaagtcaa 1440  
 catctacaga ccaactttct gacaaagaag agaagaaga aattcttcta actggcaact 1500  
 ccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560  
 tcatatgaaa atctcaggag agtaagaata aggtattcag gtctctccgt gatttgcata 1620  
 gttttctcag cattttgcag agaggcacag ttttcacaat aatattgggt atcaccagta 1680  
 agaattctctg gagcccaaaa aataatttag taagtcagtt actgaagggt tggtttcacc 1740  
 tcccggtttc tgagggtacat ctttattaac aagaattctg ttagattcgt tagggacaga 1800  
 10 agtgttttca gaacagtaaa actcattagg aggactgcct atggttttt cattcacaag 1860  
 tgagtcacag atgaaggcag ctgtgtgttg attataaact actggctctt ctgaaggacc 1920  
 ggggtacagac gcttgcatta gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980  
 gacagacatg ttttcctaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaggc 2040  
 t  
  
 <210> 17  
 15 <211> 235  
 <212> DNA  
 <213> Human  
  
 <400> 17  
  
 20 cggcccggggc aggtgtcagg ggttccaaac cagcctgggg aaacacacgc tagaccctc 60  
 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaacaa ctgtagtctc 120  
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180  
 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta  
  
 <210> 18  
 25 <211> 2732  
 <212> DNA  
 <213> Human  
  
 <400> 18  
  
 30 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60  
 tcatgttgat aactacttia tatggagctt cattggacct gtaccttca ttattctgct 120  
 aaatattatc ttcttggtga tcacattgtg caaaatggtg aagcattcaa acactttgaa 180  
 accagattct agcaggttgg aaaaacattaa gtcttgggtg ctggcgctt tcgctcttct 240  
 gtgtcttctt ggccctcacc ggtccttttg gttgctttt attaatgagg agactattgt 300  
 gatggcatat ctcttcacta ttttaaatgc ttccaggga gtgttcattt tcacttttca 360  
 35 ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420  
 ctgtggaggc ctcccactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480  
 cagtgcctcg tattccctcg gcacacagag tcgtataaga agaattgtga atgatactgt 540  
 gagaaaacaa tcagaattct cttttatctc aggtgacatc aatagcactt caacacttaa 600  
 tcaaggtggc ataatctta atatatatt acaggactga catcacatgg tctgagagcc 660  
 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagtg 720  
 40 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780  
 actataatga cagcgtgcaa gtgtgtgact gtggactaag tctgaatgat actgcttttg 840  
 agaaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900  
 acctcgagct cagctacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960  
 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggctg gagctccatc 1020  
 acaaagaact cgaggcacca cttattcctc agcggactca ctccctctg taccaaccoc 1080  
 45 agaagaaagt gaagtccgag ggaactgaca gctatgtct ccaactgaca gcagaggctg 1140  
 aagatcacct acagtcccc aacagagact ctctttatac aagcatgccc aatcttagag 1200  
 actctcccta tccggagagc agccctgaca tggagaaga cctctctccc tccaggagga 1260  
 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320  
 agatgtgcta ccagatcagc aggggcaata gtgatggtta tataatcccc attaacaag 1380  
 aaggggtgat tccagaagga gatgttagag aaggacaaat gcagctgggt acaagtcttt 1440  
 aatcatcacg ctaaggaaat ccaagggcca catgcgagta ttaataaata aagacaccat 1500  
 50 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560  
 tgggtgaaaa aagatgactg aaacctgcag ttctgtgaat ttttataaaa catacaaaaa 1620  
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaa agagatgcc 1680  
 gccaggtatt ttaagattct gctgctgttt agagaaattg tgaacaagc aaaacaaaac 1740  
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800  
 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860  
 55 ttactgtacc ttaactattc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920  
 tttgcagttc actgcaaac ctttacatta aggc aaagat tga aaacatg cttaaccact 1980

# EP 1 166 799 A1

5 agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040  
 atgaaaaaatg gctaaagaaa ttatatattg ttctatttgc agggtaaaat aaatacattt 2100  
 gtgtccaaact gaaatataat tgtcattaaa ataattttaa agagtgaaga aaatattgtg 2160  
 aaaagctctt gggtgcacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220  
 ctactcattt tccacttctt tccactgtat acagtgttct gctttgacaa agtttagtct 2280  
 tattacttac attttaaatt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340  
 tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400  
 tgtcacccct gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460  
 tttctagtga acaaaagggt cctatttctt tttaaaaaaa taaaaataaaa cataaatatt 2520  
 10 actcttccat attccttctg cctatattta gtaattaat tattttatga taaagtctta 2580  
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640  
 ttaataatga gccatcact aatatccagt gtaaagttaa acacggttg acagtaata 2700  
 aatgtgaatt ttttcaagt aaaaaaaaaa aa

<210> 19  
 15 <211> 276  
 <212> DNA  
 <213> Human

<400> 19

20 ctccctaaat gattttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60  
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120  
 tattccctat atagcaaac aaacacagga cctcccaact gcatgcctca agtccctgtg 180  
 gagcactctg gcaactggat ggcctactt gctttctgac aaaatagctg gaaaggagga 240  
 gggaaccaat aaatacctcg gccgcgacca cgctgg

25 <210> 20  
 <211> 2361  
 <212> DNA  
 <213> Human

<400> 20

30 attgtaccag ccttgatgaa cgtgggccct gcttcgcttt tgagggccat aagctcattg 60  
 cccactgggt tagaggctac cttatcattt tctcccgta ccggaagggt tctcccaagt 120  
 cagagttttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180  
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttctg 240  
 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300  
 35 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360  
 ttgccaaag cagcatctg gacagtgtat ggctggccca gattttcatg cagtatggag 420  
 accatctcta cagcaagggt aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480  
 gaaagtggga gccatcctac gtgatccgca agtttctgga tgcacagcgc attcacaacc 540  
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600  
 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatacaaga 660  
 40 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctcggcagg 720  
 ctggctacta ctcccatgcc ctgatatctg cggagaacca tgcacatcat gagtgtacc 780  
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcgcaagg 840  
 tgccttttga gcaggcagag agcaacatga agcgtacgg caagatcctc atgcaccaca 900  
 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg ccagcctcg 960  
 aaggccgag cgatagggtg gcccaggct gcagggccaa ctctgaggag ttcacccca 1020  
 tctttgccaa taacccgca gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080  
 45 cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140  
 acgagaagga tccacagggt aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200  
 gtggtcgctt ctgcgacgtc tttgacaagg ccctgttctt gtgccagatg cagacttcc 1260  
 aggatgggtt cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcaactac 1320  
 acatgcagca cgagcagtac cggcagggtc tcagcgtgtg tgagcggcat gggagcagg 1380  
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440  
 50 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctctctag 1500  
 tgggtcgac cctggcccac aactccacag ccacactctc cgtcatcagg gactacctg 1560  
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcgg 1620  
 accgagagga gaccacccgt atccgcccag agatccaaga gctcaaggcc agtcccaaga 1680  
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagtgtccc tcagtccact 1740  
 tcctgtgtgg cactccttc caccacact gctttgagag ttactcggaa agtgatgctg 1800  
 55 actgccccac ctgcctcctt gaaaaccgga aggtcatgga tatgatccg gccaggaac 1860  
 agaaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

EP 1 166 799 A1

ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980  
 ctcccacagc cagactgacc tccagcctgg aggcctgggt gcaacgcgac ctactcatgc 2040  
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100  
 5 agaacagaca caatgggacc tggcgggcg ttacacagaa ggctggctga catgccagg 2160  
 gctccactct catctaattgt cacagccctc acaagactaa agcggaaactt tttcttttcc 2220  
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cccttttaac taggcaggtg 2280  
 ttagaatcat tccagatta atggggggga aggggaacct caggcaaac tcctgaagtt 2340  
 ttggaaaaaa aagctggttt c  
  
 <210> 21  
 <211> 179  
 <212> DNA  
 <213> Human  
  
 <400> 21  
 15 aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60  
 acaatcaact aaaggaaact agagaaacct acaacacaca gcagtttagc ctggaacagc 120  
 tttataagat caacgtgaca agttgaagga aattgaaagc aaaaaattag aactaatgc  
  
 <210> 22  
 <211> 905  
 <212> DNA  
 <213> Human  
  
 <400> 22  
 25 tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60  
 caaatgttcc agttagaagg aattcaaacg gaatgccaa gtcacaagcca ggctcaagaa 120  
 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccctaagg 180  
 caaagggtact tttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240  
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtgggtggaa 300  
 tagggtcatt aataactatg aatatatctt ttagaagggt accattttgc actttaagg 360  
 30 gaatcaattt tgaatatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420  
 gggagctgga agagccttgg aagtttctat tacaatataga gcacatatac ctccatgcca 480  
 aatctcaaca aaagctcttt ttaactccat ctgtccagt tttacaata aactcgcaag 540  
 gtctgaccag ttcttggtaa caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600  
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660  
 ggcagggctc cctaattgtcc attattacat ttccattccg aatgccagat gttaaaagt 720  
 cctgaagatg gtaaccagc tagtgaggaa taaatacccc accctgcccc gtccacagag 780  
 35 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840  
 ccatggattg cagtcctctc ctccagacca gctgcttatt tcctcagggg cccagggaat 900  
 gttga  
  
 <210> 23  
 <211> 2134  
 <212> DNA  
 <213> Human  
  
 <400> 23  
 45 ggtctcttct ttctttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60  
 gtataaatac tctattttat atgcacttcc acaaaaagcg tataatttaa aagttttttt 120  
 cattagaaat aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180  
 tccttcttgg aaggaacacc caaaccaata ctataaagt acatgtaatt tatagtaaca 240  
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300  
 accaggatac gactgttggg ccagctgctg gagatggacc tgctacccct cagcagctc 360  
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420  
 50 tcattttttt tccggcggtt catcctcctt gtgtgatgtt actgattttc atgagacaca 480  
 agttacttct ttacatccat attcccagg cagggttaca tggtaggaaa gaaaggaggt 540  
 tggaggtact aagctcatcg tgtctcctct agcttttacc agcatctaat gcttcactgc 600  
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagtgtt tttttcctca 660  
 aaatgaatta cacaataaaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720  
 gttattttcac gttgtctgagc ttttctctca tgttgaaaca tctgaagttt taattctcgg 780  
 tagaaaataat gtataaacat tctctgaaac catagcagcc ataaacagt ctgggtcaag 840  
 55 atcctaattg tactccttcc tccccccatt gttagttagg taaagtaaaa caggctcttag 900

EP 1 166 799 A1

5 taaaatctca cttttctcct acctttcatt tcccaacccc catgatacta agtattttgat 960  
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttgttttt 1020  
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgccggg ggctttatta 1080  
 10 tgctatatca ctgctcagag gtttaataatc ctactactaa atcctatcaa atttgcaact 1140  
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc cactttactg 1200  
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgccttcctt 1260  
 gcaccagccc ttctcactt tgcttgccc tcaaagctaa caccacttaa accacttaac 1320  
 tgcattctgc catttgcaaa aagtctatga aatgtttagg tttctttaa ggatcacagc 1380  
 tctcatgaga taacaccctt ccactcatgg acagacactt caagcttctt tttttgtaac 1440  
 15 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500  
 ggtctgcaca aggtctggtg ctggctggtt tcaactcctt tgcacactcg gaagcaggct 1560  
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620  
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaaagt 1680  
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcaaggggca ttgccacag 1740  
 taagaacctg gatggtcaag ggtcttttga gagggctaaa gctgcgaatt ctttccaatg 1800  
 20 ccgcagagga gccgctgtac ctcaagacaa cacttttga cataatgtct tgctctaagg 1860  
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920  
 agctgcttct gttcttggat cccctctggt tccgctggtt cacttcgatg ttggtggctt 1980  
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040  
 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttttttttgg 2100  
 agtctatgat gcgatcacia ccagctttta caca  
 25 <210> 24  
 <211> 1626  
 <212> DNA  
 <213> Human  
 30 <400> 24  
 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatatttttg 60  
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120  
 atagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180  
 35 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaactg 240  
 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300  
 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaactta ttgggtcttc 360  
 atttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420  
 ggtagtgat cactggtaga aatggtttt agttattgac tcagaattca tctcaggatg 480  
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggttttag 540  
 aaagctttgt ctaaaaattt ggcctaggaa tggttaactt attttcagtt gccaaagggt 600  
 40 agaaaaataa tatgtgtgtt gttatgttta tggttaacata ttattaggta ctatctatga 660  
 atgtatttaa atatttttca tttctgtga caagcattta taatttgcaa caagtggagt 720  
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780  
 ccactctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttga 840  
 tctggaatgc attagttatg ccttgtacca ttcccagaat ttcaggggca tctgtgggtt 900  
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960  
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020  
 45 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080  
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140  
 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200  
 cgttggttct tagggttctt agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260  
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320  
 atgccagatg gtgtttatgg gctatttgtg taagtaagtg gtaagatgct atgaagtaag 1380  
 50 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440  
 tggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500  
 attatacctg tcacgcttct agttgcttca accattttt aaccattttt gtacatatatt 1560  
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620  
 aaaaa  
 55 <210> 25  
 <211> 1420  
 <212> DNA  
 <213> Human  
 <400> 25  
 60 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcatattgtc 60

EP 1 166 799 A1

5  
10  
15  
20

```

ttcattgaaa tccttgctac ttctcttctc cctcaatgaa agacacgaga gacaagagcg 120
acacaagctt aagaaaaaacg agcaaggaaag agtatcttca ttattctcat tttctctgag 180
ttggaacaa aaacatgaag gactccaact agaagacaga tatttacatc taaatagatt 240
agtgggaaaa ctttaagagt ttccacatat tagtttccat ttttgcagtc aagagactgc 300
tccttgctact gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
tattttataa ggccataaaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420
atgggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 480
ttaatgctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
aggggtggaga aagagggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
atccttttga tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
tttgctctgt ttgacctgaa gtttttagtat ttgttttcta ggtggacctc tgaataccaa 840
accagtaact ggggaggtta gatgtgtgtt tcaggcttgg agtgtatgag tgggttttgt 900
tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960
gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcttttat aggggcaggg 1020
catgagttag ggagactgaa gagtattgta gactgtacat gtgcttctt aatgtgtttc 1080
tcgacacatt ttttttcagt aacttgaata tttcaaaagg acatttggtt aggttactgt 1140
acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200
tatagaaatt ttttatactg attggttcat agatggtcag ttttgtacac agactgaaca 1260
atacagcact ttgccaataa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320
tctttgtaat tgggttgttg tgcattttgc acnacctgga gttacagttt tcaatctgtc 1380
agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

```

<210> 26  
<211> 689  
<212> DNA  
<213> Human

25

<400> 26

30  
35

```

aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
caacaaatta tagcacatcc ttctttttac tctgtctcac ctcttttagg tgagtacttc 120
cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcttta 180
ggtaatcagc ctagtttaca ctgtttccag ggagtagttg aattactata aaccattagc 240
cacttgtctc tgcaccattt atcacaccag gacagggtct ctcaacctgg gcgctactgt 300
catttggggc cagggtgatc ttctttgcaa gggctgtcct gtacctgccg gggcgccgcg 360
tcgaagcgtg gtgcgggccc aggtactgaa aggaccaagg agctctggct gccctcagga 420
attccaaatg accgaaggaa caaagcttca gggctctggg ttgtgtctcc cactattcag 480
gaggtgtgtc gaggttaacgc agcttcattt cgtccagtc tttccagtat ttaaagtgtt 540
tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
cacaccaga gcctgaagtt tgtccttcg

```

<210> 27  
<211> 471  
<212> DNA  
<213> Human

40

<400> 27

45  
50

```

tcccagcggc atgaagtttg agattggcca ggcctgttac ctgggcttca tctccttcgt 60
ccctctcgtc cattgggtggc acctgtcttt gcctgtcctg ccaggacgag gcaccttaca 120
agccctaacc caggccccgc ccagggccac cagcaccact gcaaacaccg cactgccta 180
ccagccacca gctgcctaca aagacaatcg ggccctctca gtgacctcgg ccaccacagc 240
gggtacaggc tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
tgggctgggt cccggcgagg ctgtcaatgg aggcaggggt tccagcacia agtttacttc 360
tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

```

<210> 28  
<211> 929  
<212> DNA  
<213> Human

55

<400> 28

5 ggtgaactca gtgcattggg ccaatgggtc gacacagcgt ctgccagcca caaccatcct 60  
 gctgcttctg acggttttgc tgctgggtgg ctttccccc actgtcattg gaggcattct 120  
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tccccggga 180  
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggttcct 240  
 gcctttcagc gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300  
 gcagtaacct ttgtacggca tctctctct tgtcttcgcc atcctgctga gtgtgggggc 360  
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctggtggtg 420  
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttctctact cagttttcta 480  
 ttatgcccg gctccaaca tgtctggggc agtacagaca gtagagtctt tcggctactc 540  
 cttactcact ggttatgtct tcttctcat gctgggcacc atctcctttt ttcttccct 600  
 aaagtctac cggtatatct atgttaacct caagatggac tgagtctctg atggcagaac 660  
 tattgtctgt ctctcccttt ctcatgccc tgttgaactc tctaccagc tctcttctg 720  
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttc 780  
 ccagagaggg cctggaaatt ataaatctct atcacataag gattatata ttgaactttt 840  
 15 taagtgcct ttagttttgg tctgtattt tctttttaca attacaaaaa taaaaattt 900  
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29

<211> 1775

<212> DNA

20 <213> Human

<400> 29

25 gaacgtgatg ggaacttttg gaggatgtct gagaaaaatgt ccgaagggat tttggccaac 60  
 accagaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120  
 ttgacaattc aaattgcact tggttgccgg cagcccgggc ggcttccagt ccgtgtgggg 180  
 cgcccgcggt gccttctctc cgtaggactc cccaaactcg ttcactctgc gtttatccac 240  
 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300  
 cagccggtga gacgtgggca tggatgatgat gaaggcaaa acgtcatcaa tgaagggtgt 360  
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca actttagatt 420  
 30 cacaagaagc tggggcagca tgaagaggaa accaaaaggc tagaccccg tagcgaagct 480  
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540  
 cccgacacag agaggggtaca gcaggatga caagtacttc atggcctgag tatcgtactc 600  
 ctcggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660  
 ccaaaaaata gtcattctta atgccttctt cactttccac agctcaatgg cggctccaac 720  
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780  
 caccgtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgccttctt 840  
 35 cttcttccag aaactgatgt cattttttaa gcccaggaaa tcaaagagaa gatggaacgc 900  
 tgcgacaagc aaggtcagcg ccagggaagta taagttggta tctacaaaaa ttctttcac 960  
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020  
 gtggatccag aagcgcagcc gccccagtga gaccttgcg taggacacgc tgaggggcag 1080  
 ctcggtgggt gagcggttta tgaccatcag gtcccttcac cggttgcgtg gctggctcat 1140  
 gaacaggatg ggcaggtaat gcacggtttt cccagctgg atcatcttca tgtaccgatg 1200  
 40 cacatcggca ggcaggagg acccgctcaa gacaaagtgt tccgccatca cgttcagcgc 1260  
 cagcccgcggt cgccagtggg aactggctc atccagggca ctgctcggtt tcttctccgc 1320  
 ctcgatctgc tgtgtatcag actccccggt gacgaggttg atttctctg gcttggggac 1380  
 catgtagggt gtcagaggac tgaccaggtg cactgcttc ccgtcgtgcc acggcaggac 1440  
 cccagcgtga tggagggaaga ttaggcata cagcgtccca ttgtttctcg ttttctttg 1500  
 tacagaaaac ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560  
 45 gaccaggtcg atgttgttct cagcacccag gtgggacctc gtcgtggtgt acacgctcag 1620  
 ctgcagcttg gcccgccgcg ccaggtaggg ctgcatgcag ttggcgtcgc cggagcacgg 1680  
 gcggtgttag acgatgccgt acatgaccca gcagggtgtg accacgtaga ccacgaacac 1740  
 gcccaccacc aagctggtga aggagctgcg gcccc

<210> 30

<211> 1546

50 <212> DNA

<213> Human

<400> 30

55 aaaataagta ggaatgggca gtgggtattc acattcacta cactttttcc atttgctaatt 60  
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120



EP 1 166 799 A1

5 acaccatcta cgggcaccat ggaactgctt caagtgacca ttctttttct tctgcccagt 180  
 atttgagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttggtact 240  
 acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgttggtcaca 300  
 ccaacaactg gaacaactcc taaaggaaac atcaccaatg aattacttaa aatgtctctg 360  
 atgtcaacag ctactttttt aacaagttaa gatgaaggat tgaaagccac aaccactgat 420  
 gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480  
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa cttagagttc aattaaaaa 540  
 acagaaatac caggtagtgt tctacaacca gatgcatcac ctcttaaaac tggtagatta 600  
 10 acctcaatac cagttacaat tccagaaaaac acctcacagt ctcaagtaat aggcactgag 660  
 ggtggaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tattttgccg 720  
 gtggttattg ctttgattgt aataacactt tcagtatttg ttctggtggg tttgtaccga 780  
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840  
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtcctg tgagcactct 900  
 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcaataat 960  
 tacgtttaat ctccagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020  
 15 aatcccagct tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080  
 tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tcctgttctc 1140  
 tcacatttaa aaatccatt actccattta caggagcgtt cctaggaaaa ggaatttttag 1200  
 gaggaagaat tgtgagcagt gaatctgaca gccacaggag tgggctcgct gaaggcatg 1260  
 actttcctta atgtttaaag ttttcggggc caagaatttt tatccatgaa gactttccta 1320  
 cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380  
 20 gcagggaaaa gtgacacgtg tattatttaa tattaggtag aaatcatacc atgctacttt 1440  
 gtacatataa gtattttatt cctgctttcg tggtactttt aataaataac tactgtactc 1500  
 aataactctaa aaatactata acatgactgt gaaaatggca aaaaaa  
  
 <210> 31  
 <211> 750  
 <212> DNA  
 25 <213> Human  
  
 <400> 31  
  
 30 cacttgggca cccccatctt ctaaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60  
 aaggggaagt cctctgatgg cccaaaaaac ttcttccaaa ctagtgtagg aatggaatgg 120  
 atagcaaatg gatccttttt ggcctccttt ggagcatgcc ttccctatct tatccttggc 180  
 cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240  
 aacagccttt ccctaattgg aaaatgcagt cctgtttaaa acctttgatt tacgactact 300  
 tgtacatgct tgctcatcac aattttgaca ttttttacat agtgaagacc ccaaacatat 360  
 cagtgaacaa tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttata 420  
 35 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagttatac 480  
 ttttaatagc ttccctcagca cactatttcc catgcattaa atatgataaa ataactctac 540  
 actgcccacg ggtcttgtaa aaaggaagtc tgaatacaga gcccaacaac ctaaaattgt 600  
 tttcttagct acaaaagtata gcatcatcaa cacagacacg atttgactc cctgacaggt 660  
 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720  
 ccaaaggcct tatattgtcac caccgtcccc  
  
 40 <210> 32  
 <211> 1620  
 <212> DNA  
 <213> Human  
  
 <400> 32  
  
 45 gcaattcccc cctccacta aacgactccc agtaattatg tttaacaacc attggatgca 60  
 gtgcagccat tcataagaac ctgtgtgccc cagaaaaatc tgtccttttt ggtaccaaac 120  
 ctgaggtcct ttggaagata atgtagaana ccactaccta ttgaaggcct gttttggcta 180  
 atctgtgcaa actctgatga taccctgcctt atgtggattc ttttccacac tgctttcatt 240  
 ttttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300  
 50 atgttctggg ttttttctt ctttttagaa ccccgctccc atttaaaaaa ttaaaaaaaa 360  
 aaaaaaaact ttttaacatt aaaaaataaa aatttaacaaa atttacttta ttccaggaca 420  
 cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480  
 tccataatatt tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540  
 gggtttagctt ttcaggcaac atccttggtc attgccaga aagtacctga gctatcagtg 600  
 attggaatgg cacaggaaac cgaatcacat ggggtgcccc cccttggttt tcaagtatct 660  
 55 tggagttgtg cacaaaaatt aggtcatgcc ttcagtgtct tgttctttta acctaccctt 720  
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaatgt 780

	gtgttctctcc	taggttggaa	gaaatgtctt	tccctctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgaatgtcaat	taagtttcag	gtttggcatg	atcatcatte	tcgatgatat	tctcactttg	960
5	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	tccctccac	tataccactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtag	caaacctgag	gtcttttggg	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactcg	tgcacactct	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgcttt	cattttttaag	tataaagact	tagaaaaacta	gaataatgct	1260
	tttacaataa	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaacctgtg	1320
10	atttaaacaa	gccttctttt	taagctttgt	tggaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaat	gtgtaactta	agggtattat	atatataaat	1560
	acatatatac	ctttgtaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
15	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
	<400> 33						
20							
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggagggagga	agaggaggga	120
	gaaagtgaag	gcagtgaaag	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaaagtaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaaga	agaaaaggct	tatgacaaaag	caaaaacggag	gattgagaaa	300
25	cgggcagctt	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
	gtactttggg	atgtggacac	agggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagc	tggatcacac	caacaaattg	gggccaccaa	tgttctctct	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaaagctct	ttttgacat	tgccatttta	gttgttgata	ttatgcatgg	tttgagagccc	660
30	cagacaattg	agtcctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgacttc	720
	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	ctttgtgacc	tacctctgca	catactggtg	atggcatggg	aagtctgac	960
	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgacac	ctgtgaagag	1020
35	ctgagagcac	agggtatgga	ggtttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaaggaaagga	gatacaatca	ttgttctctg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctctct	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattcttgga	1260
	aaagacctgg	agaaaacatt	ggctggttta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttctttgga	agctctactg	1440
40	gaattttctg	aaacatcaga	agtgccctat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtaa	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	acttttagtg	cageaattat	ttatcattta	tttgatgcct	ttacaaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtgga	1800
45	gcaggtcagg	tgaaacaggg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgacatc	1860
	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atggtgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaataga	acctatccct	ggtgagtcac	ccaaaatggt	tggaaagacat	1980
	tttgaagcta	cagatattct	tgttagtaag	atcagccggc	agtcatttga	tgcactcaaa	2040
	gactgggtta	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcacttaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
50	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgagt	2220
	gacttaagta	tggaaaggaa	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccctcccca	acccttctct	acttggctgc	tgttttaaa	tttgcccttc	2400
	cccaaatttg	gatttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
	gtactgcagt	atttggattaa	aaaaaataaa	gcagattttg	tgattcttgg	gacttttttg	2520
55	acgttaagaaa	tacttcttta	tttatgcata	tcttccccac	agtgattttt	ccagcattct	2580
	tctgccarat	gccttttaggc	cttttataaa	atagaaaaat	aggcatctg	atatttcttt	2640

# EP 1 166 799 A1

5 agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttctgt 2700  
agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760  
catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820  
agttgtcttc ctagcacaag gaattatctt aacaaactaa actatccatc acactacctt 2880  
ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgttttaac 2940  
tgatcggttt agtagagatt ttatacat

<210> 34  
<211> 6011  
<212> DNA  
10 <213> Human  
  
<400> 34

15 acggggcgcc ggacgacccg cacatcttat cctccacgcc ccaactcgac tcggagcggg 60  
accgcccccg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120  
cggccttgagc cgagcgagc acccccgcg ccccgcgcca gaagtctggg tgaaccgggc 180  
tgccgggaga aacttttttc tttttcccc ctctccggg agagtctctg gaggaggagg 240  
ggaactcccc cgccccaagg ctctgtgggt cggggtcgcg cgcccgacaga aggggcgggg 300  
20 tccgcccgcg aggggaggcg cccccggga cccgagaggc gggtagggac cgcgggctgc 360  
tggtgcggcg gcgcgagcgt gtgcccgcg caggggaggc gccgccccgc tcccgccccg 420  
gctgcgagga ggagcgcgcg gcgcgcgagg aggatgtact tggtagcggg ggacaggggg 480  
ttggccgggt gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccgcgcgcg 540  
tccggcaccc ggcgctgggt ctgctgccc tgtgacgagt ccaagtgcga ggagcccagg 600  
aaccgcccgg ggagcatcgt gcaggcgctc tgcgctgct gctacacgtg gccagcccag 660  
25 gggaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgacgg ggggctgctg 720  
tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcggttgc 780  
gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840  
attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900  
aatccctttg agtttccaag tcaggatatg tgcctttcag ctttaaaagag aattgaagaa 960  
gagaagccag attgctccaa ggcccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020  
30 gattctgttc tgatcgaggc ttatgctcct cctggggagt gctgtccctt acccagccgc 1080  
tgctgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140  
ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaaaa 1200  
gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260  
ccggacagct atgaaactca agtcagacta actgcagatg gttgtgtgac ttgccaaca 1320  
agatgcgagt gtctctctgg cttatgtggg ttcccctgtg gtgaggtggg atccactccc 1380  
35 cgcatagtct ctctggcgga tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440  
aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500  
cgaatggaca actgtcggtt ctgtcgatgc caaggggcg ttgccatctg cttcaccgcc 1560  
cagtgtgtgt agataaactg cgagaggtac tacgtgcccc aaggagagtg ctgcccagtg 1620  
tgtgaagatc cagtgtatcc ttttaataat cccgctgggt gctatgcaa tggcctgatc 1680  
cttgcccacg gagaccgggt gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740  
40 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800  
ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860  
ggggagttat caaactgcac tctgacacgg aaggactgca ttaatgggtt caaacgcgat 1920  
cacaatggtt gtcggacctg tcagtgcata aacacccagg aactatgttc agaacgtaaa 1980  
caaggctgca ccttgaactg tcccttcggt ttccctactg atgccaaaa ctgtgagatc 2040  
tgtgagtgcc gcccaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100  
45 ctggatttgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160  
ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttatc 2220  
tgcaagtgca gagagccctc tgcttcagct gggccaccca tccgtgaggc cacttgtctc 2280  
accgtggatg gtcatcatca taaaaatgag gagagctggc acgatgggtc ccgggaatgc 2340  
tactgtctca atggacggga aatgtgtgcc ctgatcacct gccgggtgcc tgcctgtggc 2400  
aaccaccaca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgcag 2460  
aagccagagc tcagtactcc ctccatttgc cagccctcg gaggagaata cttgtggaa 2520  
50 ggagaaacgt ggaacattga ctccgtact cagtgcacct gccacagcgg acgggtgctg 2580  
tgtgagacag aggtgtgccc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640  
tgctgcccac agtgtacaga tcaacctttt cggccttcct tgcctccgaa taacagcgta 2700  
cctaattact gcaaaaatga tgaaggggat atattccctg cagctgagtc ctggaagcct 2760  
gacgtttgtc ccagctgcac ctgattgat agcgtaatga gctgtttcc tgaagcctgc 2820  
cctctctgat cctgtgaaag acctgtcttg agaaaaggcc agtgtgttc ctaactgcata 2880  
55 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccca tgccgacgag 2940

EP 1 166 799 A1

gagcgggtggg accttgacag ctgcacccac tgctactgcc tgcagggccca gaccctctgc 3000  
 tcgaccgtca gctgcccccc tctgcccgtg gttagagcca tcaacgtgga aggaagtgc 3060  
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120  
 5 aaccatcgag gagagggtga cctggagggt cccctgtggc ccacgcctag tgaatatgat 3180  
 atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240  
 cacccaagtg aagattcttc actggactcc attgcctcag ttgtgggtcc cataattata 3300  
 tgccctctcta ttataatagc attcctatcc atcaatcaga agaaacagtg gataccactg 3360  
 ctttctctgtg atcgaacacc aactaagcct tcttccctaa ataatacagc agtatctgtg 3420  
 gactgcaaga aaggaaccag agtccagggt gacagttccc agagaatgct aagaattgca 3480  
 10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540  
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600  
 gacgactaaa tctgctctaa aaagtaaaact agaatttctg cacttgctta gtggattgta 3660  
 ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720  
 atgtgcagaa caagcattcc cacttttccct caagataact gaccaagtgt ttctctagaa 3780  
 ccaaagtgtt taaagtgtct aagatatatt tgccctgtaag atagctgtag agatatttgg 3840  
 15 ggtggggaca gtgagtttgg atggggaaag ggggtggagg gtggtgttgg gaagaaaaat 3900  
 tggtcagctt ggctcgggga gaaacctggt aacataaaag cagttcagtg gccagagggt 3960  
 tatttttttc ctattgctct ctgggttctg ctgggttctg caaagctcag gctggaatga 4020  
 gcaggaaaca aaaaaggcct tgcgaccag ctgccataac caccctagaa ctaccagacg 4080  
 agcacatcag aacccttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140  
 cagtcacaac tgcagtggc agtgaggaa cagagaaat gcgatacgcg catttctcta 4200  
 20 aagcgggtta ttaaggatat atacagttac acttttctg gcttttattt tcttccaagc 4260  
 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatctcttg 4320  
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggagggt agagggtgac 4380  
 gaacaccagg catctccagg ggctatattt cactgtttgt tgttgctttg tctgttata 4440  
 ttgttgggtt ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500  
 gactgttttg ggattctttt tcttatttat atactgattc tacaaaaatag aaactacttc 4560  
 25 attttaattt tatattattt aagcaccttt gttgaagctc aaaaaaaatg atgctctttt 4620  
 aaacttttagc aattatagga gtatttatgt aactatctta tgcctcaaaa aacaaaagta 4680  
 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740  
 tgttttcttg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800  
 cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcatte 4860  
 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920  
 30 gtgtgtgtgc gcgcacgcac gccttgagca gtcagcattg cactgtctat ggagaagggt 4980  
 attcctttat taaaatcttc ctcatattgga ttgtcttca gttggttttc aatttgctca 5040  
 ctggccagag acattgatgg cagttcttat cgcacatcct aatcagctcc tggatttttt 5100  
 tttttttttt tcaaacatag gtttgaacaa actactggaa tattgtccac aataagctgg 5160  
 aagtttgttg tagtatgcct caaatataac tgactgtata ctatagtgggt aacttttcaa 5220  
 acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280  
 35 tgcttgttgt gaaagacaca gataccaggt atgcttaacg tgaaaagaaa atgtgttctg 5340  
 ttttgtaaag gaactttcaa gtatttgtgt aaatacttgg acagagggtg ctgaacttta 5400  
 aaaaaaatta atttattatt ataataacaa aaggtgttct agctgtttgc atcaaaggaa 5520  
 ttgtcttaga atattcaagg ggcaatattt ttatcttttc caaaaataat ttgttaatga 5580  
 aaaaagattt atattcaagg acatcagcct gattagtata aattttgttg gtaattaatc 5640  
 tacattacaa caatcatggc atatttatga aaatactaac aggatatagg acaaggtgta aattttttta 5700  
 40 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5760  
 caatcatggc catatttatga aaatactaac aggatatagg acaaggtgta aattttttta 5760  
 ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttactttggg 5820  
 tctgtgtgtg ctcttgtaaa agaaaaatat aatttcttga agaataaaat agatatatgg 5880  
 cacttgaggt gcacatagtt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940  
 gaatttatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000  
 aaaaaaaaaa a

<210> 34a  
 <211> 1036  
 <212> DNA  
 <213> Human

<400> 34a

mylvagdrql agcghllvsl lgiillpars gtralvclpc deskceepn rpgsivqgvc 60  
 gccytcasqg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120  
 55 gfkpcnenli agcnliingkc ecntirtcsn pfefpsqdmc lsalkrieet kpdcskarce 180  
 vqfspirped svliegyapp gecclpsrc vcnpagclrk vcqpgnlnil vskasgkpgc 240

5 ccdlyeckpv fgydertvec pttvqqtacpp dsyetaqvrlt adgccttlptr ceclsglcgff 300  
 pvcevgstpr ivsrgdgtpp kccdvfecvrn dtkpacvfnn veyydgdmfir mdncrfrcrcq 360  
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420  
 ctfcqcvnge rhcvtatvcgq tctnrvkvpg eccpvceapt iitvdppacq elsnctltkr 480  
 dcingfkrdh ngcrccqcin tqelcserkq gctlncpfgf ltdagncelc ecrprpkker 540  
 piicdkycpl gliknkhgdc icrckkcpel scskicplgf qqdshgcllc kreasasag 600  
 ppilsgtclt vdghhkhknee swhdgcrecy cingremcal itcpvpacgn ptihpgqccc 660  
 scaddfvvqk pelstpsich apggeyfvvg etwnidsctq ctchsgrvlc etevcppllc 720  
 qnpsrtqasc cpqctdqpfr pslsrnnsvp nycndegdi flaaeswkpd vctscicids 780  
 10 vscfscscsp svscerplvr kgcccpycik dtipkkvch fsgkayadee rwdldsthc 840  
 yclqgqtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekn hrgevdlevp 900  
 lwptpsendi vhlprdmghi qvdyrdnrh psedssldsi asvvvpiic lsiiiaflfi 960  
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgttrvqvd ssqrmiriae pdarfsgfys 1020  
 mqkqnhlqad nfyqtv

15 <210> 35  
 <211> 716  
 <212> DNA  
 <213> Human

20 <400> 35

25 gcagtagctg gagggtcctg cagggggaaa gccaaccggg ccctgaagtc cggggcagtc 60  
 acccggggct cctgggcccgc tctgccgggc tggggctgag cagcgatcct gcttgtgcc 120  
 agaagtccag agggatcagc ccagaacac accctcctcc ccgggacgcc gcagctttct 180  
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaaagaattt 240  
 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag agcagggggc 300  
 ttgagggaat ctctgattc tctttatatg acctcaaaact gaccatacta aacagtgtag 360  
 aagggtcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420  
 gtcagtgtgg agtagacggg ttctccacc cagggttgac tcagggggat gatctgggtc 480  
 ccattctggt cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540  
 tctggttagt gtcgtaacct ctggtgtcct ccggttacc catctgtcca gtgagctcag 600  
 30 ccccatcca cctaacaggg tggccacagg gattactgag ggttaagacc ttagaactgg 660  
 gtctagcacc cgataagagc tcaataaatg ttgttcctt ccacatcaaa aaaaaa

<210> 36  
 <211> 395  
 <212> DNA  
 35 <213> Human

<400> 36

40 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60  
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcc tttactacat 120  
 tctccaaaaa aaccttgaaa tgaagaaggc caccctaaa atacttcaga ggctgaaaaa 180  
 atgattatta cattggaatc ctttagccta tgtcatattt cttaacttt gcactttcac 240  
 gccagtaaaa accaaagtca gggttaacaa tgtcatattt caaatgtta aaaccctaata 300  
 tgcagttcct tttttaaat attttaaga ttacttaaca acattagaca gtgcaaaaaa 360  
 agaagcaagg aaagcattct taattctacc atcct

45 <210> 37  
 <211> 134  
 <212> DNA  
 <213> Human

<400> 37

50 ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60  
 aaccataaaa gctgcctggc ttccagcaac aggcctatca acaccatggg gactctccat 120  
 aaggacacac gtgt

<210> 38  
 <211> 644  
 55 <212> DNA

<213> Human

<400> 38

5

aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60  
 cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120  
 gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180  
 ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240  
 gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300  
 10 ttcagagcca ggctgtaaaa attaaaaatga acasattacg gcaaaagtttt aggagaaaga 360  
 aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420  
 ttcgcaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480  
 caagaggaaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540  
 tcaaaaggctt ctttgaaaaa actggaaaaga aagcagttaa agcagtttct gtgggtctaa 600  
 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

15

<210> 39  
 <211> 657  
 <212> DNA  
 <213> Human

20

<400> 39

ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60  
 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120  
 gcctcccaac taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180  
 tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240  
 25 acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtgaaaaaac 300  
 agcaaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaatttc 360  
 tggctccttg agcaaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420  
 ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480  
 aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540  
 taagaaatag tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600  
 atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

30

<210> 40  
 <211> 1328  
 <212> DNA  
 <213> Human

35

<400> 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60  
 ctggttagtt tttgtaggct cattatggtt aggttcgtta agatgtatat aagaacctac 120  
 ctatcatgct gtatgtatca ctcatcccat ttctatgttc catgcatact cgggcatcat 180  
 40 gctaataatgt atccttttta gcaactctca ggaacaaaaa gggcctttta tttttataaa 240  
 ggtaaaaaaa attccccaaa tattttgcac tgaatgtacc aaaggctgaag ggacattaca 300  
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360  
 acttccctca cagtgccttg tctaccacta caaggactgt gcatctaagt aataattttt 420  
 taagattcac tatatgtgat agtatgatag gcatttattt aaaatgcatt agactctctt 480  
 ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540  
 gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600  
 45 tgaagagatc agtagtaaga attccatttt cctcatcag tgaagacacc acaaatgaa 660  
 actcagaact atatttctaa gcctgcattt tcaactgatc ataattttct tagtaatat 720  
 aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780  
 ttaattttat gagaaggtat tcttcatttt aattgctttt gggattactc cacatctttg 840  
 ttattttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaaagc 900  
 atcggattga catatgggtt gccagcctat gggtttacag gcatgtccca aacattttct 960  
 50 tgagatctat atttataaag agccatggaa ttcttattat gggatgttgg caatcttaca 1020  
 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080  
 gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140  
 ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200  
 tggaaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260  
 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320  
 tgaaaaaa

55

EP 1 166 799 A1

<210> 41  
 <211> 987  
 <212> DNA  
 5 <213> Human  
  
 <400> 41  
  
 aacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60  
 tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120  
 10 taacccccgg ctatcagtcg ggaatggtgc cacccttcct gctgtaggat ggaagcagcc 180  
 atggagtggg agggagggcg aataagacac cctccacag agcttggcat catgggaagc 240  
 tgggtctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300  
 tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360  
 aaacacagct gccaggagcc caggcacagg gctgggggcc tggaaaaagg agggcacaca 420  
 ggaggaggga ggagctggta gggagatgct ggctttacct aagggtctcg aacaaggagg 480  
 15 gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540  
 tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600  
 gaacaagcac aggccttggg atccaatgga ctgaatcaga accctaggcc tgccatctgt 660  
 cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720  
 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780  
 aatagtctac ggccatacca cctgaacgtc gcctaatac gtaagctaa cagggtcagg 840  
 20 cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgag ttggagtgg 900  
 actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960  
 tgaagtagcg atttggtgtg aaaaaaa  
  
 <210> 42  
 <211> 956  
 <212> DNA  
 25 <213> Human  
  
 <400> 42  
  
 cggacggtgg ggccggacgcg tgggtgcagg agcagggcgg ctgccgactg ccccaaccaa 60  
 ggaaggagcc cctgagtcg cctgcgcctc catccatctg tccggccaga gccggcatcc 120  
 30 ttgccgtgtc aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180  
 tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcagg 240  
 caggcgtgtg gcagccacac gcaggcgcc agggcgggcca gggaccctaa gcaggatgac 300  
 caccgacctc caccgcaactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360  
 tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgtctgtg acagatggac 420  
 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaa 480  
 35 gagattgctg gaaaccaagt caggccaggt gggcggaaca aagggccagg tgcggcctgg 540  
 ggggaacgga tgctccgagg actggactgt ttttttcaca catcgttgcc gcagcgttgg 600  
 gaaggaaagg cagatgtaaa tgatgtgttg gtttacagg tatattttt ataccttcaa 660  
 tgaatttaatt cagatgtttt acgcaaggaa ggacttacc agtattactg ctgctgtgtc 720  
 tttgatctct gcttacgtt caagagcggt gtgcaggccg acagtcggtg accccatcac 780  
 tcgcaggacc aaggggggcg ggactgctgg ctacgcgcc gctgtgtcct cctccccctc 840  
 40 ccttccttgg gcagaatgaa ttcgatgcgt attctgtcgc cgccatctgc gcagggtggt 900  
 ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa  
  
 <210> 43  
 <211> 536  
 <212> DNA  
 45 <213> Human  
  
 <400> 43  
  
 aaataaacac ttccataaca tttgttttc gaagtctatt aatgcaatcc cacttttttc 60  
 cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttccctcac 120  
 50 agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180  
 ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240  
 tctaataaaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300  
 cattctcatc ccttaacaga caaaaactta ttgtcaaaa gaattagaaa aggtgaaaat 360  
 attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420  
 ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480  
 55 agggtaggtt ccccgccacc tggacctgga caggtagggc tccgtggtta accagt

EP 1 166 799 A1

<210> 44  
 <211> 1630  
 <212> DNA  
 <213> Human

5

<400> 44

ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60  
 gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120  
 10 tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180  
 atccctctg gaggaagag gcaggaaaat tctcccggg tccctgtcat gctactttct 240  
 ccatcccagt tcagactgtc caggacactc tatctgcagc cataagagaa ttataaggca 300  
 gtgatttccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tgggcccaat 360  
 catggcaggt tctgggtca aagctgaact ggggagagaa gagatacaga gctaccatgt 420  
 gactttacct gattgccctc agtttgggt tgcttattgg gaaagagaga gacaaagagt 480  
 15 tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540  
 gacaggattg gctcagatga cccctgaggg ctctccagt cttgaaatgc attccatgat 600  
 attaggaagt cgggggtggg tgggtggtgt ggcctagtgt ggtttgaatt taggggccga 660  
 tgagcttggg tacgtgagca ggggtgtaag ttagggtctg cctgtaattc tgggtcccctt 720  
 ggaatgtcc ccttcttcag tgtcagacct cagtcaccagt gtccatatcg tgcccagaaa 780  
 agtagacatt atcctgcccc atccccctcc cagtgcactc tgacctagct agtgccctgtt 840  
 gccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900  
 20 tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960  
 gagttggctg gtagagcctt cttagaggttc agaataatag cttcaggatc agctgggggt 1020  
 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080  
 tgagggacag tttgggtttg ggacttacca ggggtatgtt agatctggaa cccccaagtg 1140  
 aggctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200  
 aaagagtgac cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260  
 25 gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320  
 ctgggtccct tgtagcacag gagactgggg ctaagggcc ctcccaggga agggacacca 1380  
 tcaggcctct ggctgaggca gtagcataga ggtccattt ctacctgcat tcccagagg 1440  
 actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500  
 cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560  
 30 cctcttgctt cttgtagaat gcagctcagg cctcaataa atgcttctg cattcatctg 1620  
 caaaaaaaaa

<210> 45  
 <211> 169  
 <212> DNA  
 <213> Human

35

<400> 45

tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60  
 taaaactggt ttatgatctt cagtctgatt ccagtctgc ataactagat aacgtatgaa 120  
 ggaaaaacga cgacgaacaa aaaagtaagt gcttgaaga cttagttaga

40

<210> 46  
 <211> 769  
 <212> DNA  
 <213> Human

45

<400> 46

tgcaggatcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtga 60  
 atttgcctgct ttacattttt ataaagtgtc acataaaatg tcataatttc aaatttaaaa 120  
 acataaactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180  
 aaacaaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240  
 50 aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300  
 ccaagagaag ttatgaattt aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360  
 cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420  
 ggcagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480  
 catgccagtg aatgagaaaa caagcatgga atatataaac ttttaacatta aaaaatgttt 540  
 tattttgtaa taaaatcaaa tttccattg aaaccttcaa aaactttgca gaatgaggtt 600  
 ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660  
 55 cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720



EP 1 166 799 A1

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47  
 <211> 2529  
 <212> DNA  
 <213> Human

<400> 47

10 tttagtcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaca 60  
 gtgaaaatta gtgactgggt aagggtggcc actgtacata tcatcatttt ctgactgggg 120  
 tcaggacctg gtccctagtc acaagggtgg caggaggagg gtggaggcta agaacacaga 180  
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240  
 ggatgggtgg aaggggggtc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300  
 gccttactta gctcctggca gaggtgagt ggggacctac gaggttcaaa atcaaatggc 360  
 15 atttggccag cctggcttta ctaacagggt ccagagtgc ctctgttggc tgagctctcc 420  
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctacct acaacttttc 480  
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540  
 actagtggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600  
 ccagaggccc ctgcaacttt gcgattttcc agaaggtgat aaaaagagca ctcttgagt 660  
 ggtgccagg aatgtttaaa atctatcagg cacactataa agctggtggt tcttccctac 720  
 20 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780  
 tgaactctgg tgttgacagg tacaaggagc aagagatggg gactgtgaag aggggagggc 840  
 ttccctcatc ttccctcaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900  
 gcaatagatg gggcttccca ccatttgggt gttattgctg gggtagcca ggagcaggt 960  
 ggatggcaaa gtaggagaga ggcccagagg aaagcccctc tccctccagc tttgggggtct 1020  
 ccagaaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080  
 25 aggtgaacag tcttacctgc ttggtacctat agtccctcaa taagattcag aggaagaagc 1140  
 ttatgaaact gaaaaatcaa tcaaggtatt ggaagaata atttccctc gattccacag 1200  
 gaggggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260  
 acaaatcatc aggggttggc tggctggcag tcacatgctt ccttggtttt agcacacata 1320  
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380  
 ccttttcttc gctcttctc aaaagacaac ttggcttctg aggatgggtg tcttttgcac 1440  
 30 gcagttgggc tgacctgaca aagccccagc ttctctgtgg caggttctgg gagaggatgc 1500  
 attcaagctt ctgcagccta ggggacaggc ctgcttgttc agttattact gcctcggagc 1560  
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagttcag 1620  
 ctctggcagc attctcggc gtatgttttc tggcagagag aggcagatga acatagtttt 1680  
 agggagaaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740  
 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800  
 35 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860  
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920  
 gggggagtgg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980  
 ctctatctga ggagcccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040  
 tgaaaatttc cagaaatacc atttgggtga tccctttgtt tctgtaatat taaactcagg 2100  
 tgaaaattata ctctgacagc ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160  
 40 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220  
 gcctgaagtt atagagtgt tacagcgggt gcgatattca ggggtcatcg ccaactggtc 2280  
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atccactga 2340  
 ttccaggagt caagattagc caggaaagca aacaccagga gttgggggtg cacgtacca 2400  
 gtccagagcc ctgccacgga tgtacgcagg agccacagcat taggcaatca ggagccagaa 2460  
 catgatcacc agggccacaa atagggaagag gcgtgacagg aactgctcgt ccacatacct 2520  
 ggggtgtcc

45 <210> 48  
 <211> 1553  
 <212> DNA  
 <213> Human

50 <400> 48

55 tttttttttt tttttgattt ctgggacaaat taagctttat ttttcatata tatatatatt 60  
 ttcatatata tatatacata catatataaa ggaacaatt tgcaaattra cacacctgac 120  
 aaaaccatat atacacacac atgtatgcat acacacagac agacacacac acccgaagct 180  
 ctagccaggc ccgttttcca tccctaagta ccattctctc atttgggccc ttctagggtt 240  
 ggggccctga ccttgggttg tagaagtttg gtgctaatat aacctagct ttaatccca 300  
 tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

EP 1 166 799 A1

5 ccatcaagag ggctatggga gccaaagtga cacgggggat tgaggcta tccactgaac 420  
 tccaaaacag cggccagcct cctcaccgca ggcacgcctc ttttctttt ttttctcga 480  
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggctctg gctcactgca 540  
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600  
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660  
 caccgtgtta gccaggatgg tctcgtcctg acttttgtat ccgcccgcct cggcctccca 720  
 aagtgtctggg attacaggcg tgagccacca caccgggcc cggcacgtat cttttaagga 780  
 atgacaccag ttcttggtct ctgaccaaaag aaaaaatgtc acaggagact ttgaagaggc 840  
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggtgtctctc 900  
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960  
 acttcagtgg tgcacctgga tgggtggaagc cagcctttgg ggcaggaaac cagctcagag 1020  
 aggctaccca gctcagctgc tggcaggagc caggatattt cagccataat gtgtgtaaa 1080  
 aaaaaacacg ttctgcaaga aactctccta ccgctcggg agactggggc tctttgcttg 1140  
 ggatgagctt cactcaacgt ggagatggtg gtggactggt cctgaaaag cgggccttgc 1200  
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260  
 cgaggggagc aggaggcttc tctctagctc ctttggaagg tttggctgag agaagagtga 1320  
 gcaggggagc gggaatggtc caggcaggga agggagctga agtgattcgg ggctaattgc 1380  
 tcagatcgat gtatttctct cctggtctc ccggagccct cttgtcaccc ctgctgcctc 1440  
 gcaggaggcc catctctctc tggagcttat ctgacttaac tcaactaca agtctgctct 1500  
 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag  
  
 20 <210> 49  
 <211> 921  
 <212> DNA  
 <213> Human  
  
 <400> 49  
  
 25 ctgtggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagttgga 60  
 tgttgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataacct 120  
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcgttcta cgggaaaacc 180  
 gctctgcaga acacttggtc actcctaccc cagatcagtg gacctgggaa tgagggttgg 240  
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300  
 30 gaagcctccc ggggagtgg ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360  
 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420  
 tgcgtgcttg tgtgtgtgct tgcccctccc ctgcagccgt cgggtgtatc tccctccagc 480  
 cccttcgcca ccttctgagc attgtctgtc cactgagac tgcccagaga cagcagagct 540  
 ccacgtggtt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600  
 cagggtgctaa atgaccogac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660  
 35 gtcccgcctga cctgccccgg tggcgtctca cgggtgatgc tgctcctgac attggtgttc 720  
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780  
 ttcaataaaa atggacttga tttagaagag caaaaagctg tgtggtcctt ccagcacgga 840  
 tactttgacc tcttgccctac aaccctctcc ttgggtccga ggtggttagc tttgttact 900  
 tcagatgggt gggggcgggt g  
  
 40 <210> 50  
 <211> 338  
 <212> DNA  
 <213> Human  
  
 <400> 50  
  
 45 atgatctatc tagatgcctt accgtaaaa caaaacacaa aaccctactg actcattccc 60  
 tcccttcag atattacccc atttctctac tcccattgt agccaaactt tccaaaaatt 120  
 catgttctgt cttcatttcc tcatgttcaa cccacctgt cttagctacc acccctcagt 180  
 aacgacctag cctgggtaga aacaaatgtc agcatgata catactcaat gatccttcgt 240  
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300  
 gtaagaaact ttctttcttg aattcttggc tctcttgg  
  
 50 <210> 51  
 <211> 1191  
 <212> DNA  
 <213> Human  
  
 <400> 51  
  
 55

EP 1 166 799 A1

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccgggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tgttggctct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
5	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
	aaactttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acacctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgctcgga	gacgctcctg	acaagtcggg	360
	aattttctcta	ttttctccact	ggtgcaaaga	gcggatttct	ccctgcttct	cttctgtcac	420
	ccccgtctct	ctccccaggg	aggctccttg	atttatggta	gctttggact	tgcttccccg	480
	tctgactgtc	cttgacttct	agaatggaa	aagctgagct	ggtgaaggga	agactccagg	540
10	ccatcacaga	taaaagaaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gagggagaaa	tggtctctag	660
	atggaatcag	cagcggaaaa	gaacggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accgatccca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
	aaaaagctga	actgcaaata	tcaacgaagg	aagaggccat	tttaaaagaa	ctaaagtcaa	840
	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
15	aagagtcatt	tgaggacatc	tatgctaata	tccttgacct	tccaaagtcc	tacataacct	960
	ctagggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagcct	1020
	tatatgccat	ggaaattaaa	gttgaaaaag	acttgaagac	tggagaaagt	acagttctct	1080
	cttccaatac	ctctggccat	cagatgacct	taaaaggtac	aggagttaaa	gtttaagatg	1140
	atgggcaaaa	gtccagtgtg	ctcagttaag	tgctaatacac	aagttggagg	t	
	<210>	52					
20	<211>	1200					
	<212>	DNA					
	<213>	Human					
	<400>	52					
25	aacagggact	ctcactctat	caaccccagg	ctggagtcgg	gtgcgcccac	cctggctccc	60
	tgcaacctcc	gcctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	tttttgtaga	gacagggttt	180
	cgccttctgt	ccaggccggc	atcataact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcaggtttg	tttaaaaata	attgcttttt	tattattttt	gcattttttg	300
	accaaacctta	atgctatgta	aatagttgtt	atactgttgc	ttacaacacg	tatgacaatt	360
30	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtg	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaacc	acagatatga	480
	agggtctggc	atatatgcat	tgatgattgt	cctatttat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagtatatg	tacagtggaa	agagttagtg	aaaacataaa	catttggacc	600
	tttcaagaaa	ggtagctttg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggtcc	660
	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagctc	cagttgcctc	720
35	acctgtaaaa	tgaagaact	ggatactctc	taaggctact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaa	840
	gattattaaa	gtgggaaaaa	gccaattgct	tctcttagaa	agctcaacta	aatttgagaa	900
	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
	agagatgggg	tctcactctg	tcacccagac	tgaggtacag	tggcacaaat	atagctcact	1020
	gctgcctcaa	attcatgggc	tcaagtgate	ctcctgcctc	tgccctccaga	gtagctgcga	1080
40	ctatgggcat	gtgcccacc	gcctggctaa	catttgtatt	gacctattta	tttatctgtg	1140
	tttatatctt	tttttttttt	tctttttttt	ttttttacaa	aatcagaaat	acttattttt	1200
	<210>	53					
	<211>	989					
	<212>	DNA					
45	<213>	Human					
	<400>	53					
	aagccaccac	tcaaaaacttc	ctatacattt	tcacagcaga	gacaagtga	cattttattt	60
	tatgcctttc	ttcctatgtg	tatttcaagt	ctttttcaaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tcgaggagtc	cagggagcct	ctacaaatgc	180
50	agagtgaact	tttaccacaa	taaaccttag	atacatgcaa	aaagcaggac	ccttccctcca	240
	ggaatgtgac	atctcagatg	cacagacccc	atgcagaaaa	gctggaattt	tccttggaac	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgcaatg	cgtgatctca	ctcactgcaa	ttccacctcc	420
	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacagccac	tgccaccatg	480
	ccgggctaatt	ttgtattttt	gtagagatgg	atcttctccat	ttggtcaggc	ggtctcgaa	540
55	cccaacctca	gagatctgcc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

# EP 1 166 799 A1

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660  
 ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720  
 atttaccgca gttttgcacc taagagtatg acaacagcaa taaaaagtaa ttccaaagag 780  
 5 ttaagatttc ttccagcaaaa tagatgatcc acatcttcaa gtccctttttg aaatcagtta 840  
 ttaatatatt tcttttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900  
 tttttttttt ttgcgagatg gaatctcgtc ctgtcgccca gcgggagtg cactggcgcaa 960  
 gcccggtcga ccgcaatctc tgccacccg  
  
 <210> 54  
 <211> 250  
 10 <212> DNA  
 <213> Human  
  
 <400> 54  
  
 15 catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60  
 gcagaggcta ctacaagaag tagggaaatca agtccctcac atgggctatt aaaactaggt 120  
 agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180  
 aaagggcatt ctttaggaac tgcattctgt aacccacacc ttgatccaag agctagggaa 240  
 acttcagttg  
  
 <210> 55  
 <211> 2270  
 <212> DNA  
 <213> Human  
  
 <400> 55  
  
 25 gcgcccccg gacgcgcgcg cgcctccgcg gccttctccg ccgggacctc gagcgaaaaga 60  
 ggcccgcgcg ccgcccagcc ctgcgctccc tgcccaccgg gcacaccgag ccgcccacccc 120  
 gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgctct ctgcgcccgc 180  
 ctgcgcccgc gctactctct cgcgcccaca tgagctcccc catcgccagg gcgctcgctt 240  
 tagtcgtcac ccttctccac ttgaccaggc tggcgctctc cactgcccc gctgcctgcc 300  
 actgccccct ggagcgcccc aagtgcgcgc cgggagtcgg gctggctccg gacggctgcg 360  
 30 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccccgcg 420  
 accacaccaa ggggctggaa tgcaacttcg gcgccaagt caccgctctg aaggggatct 480  
 gcagagctca gtcagagggc agacctgtg aatataactc cagaatctac caaaacgggg 540  
 aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600  
 ttccctctgtg tccccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggttgg 660  
 tcaaagttac cgggcagtg cgcgagaggt gggtctgtga cgaggatagt atcaaggacc 720  
 35 ccatggagga ccaggacggc ctccctggca aggagctggg attcgatgcc tccgaggtgg 780  
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggtctc 840  
 ctgttttttg aatggagcct cgcactctat acaacccttt acaaggccag aaatgtattg 900  
 ttcaaaaca ttcatgttcc cagtgtctaa agacctgrgg aactggtatc tccacacgag 960  
 ttaccaatga caacctgag tgccgccttg tgaaagaaac ccgattttgt gaggtgcggc 1020  
 ctgtgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080  
 40 aatcccccg accagtcaag tttactaac ctggatgttt gactgtgaag aaataccgc 1140  
 ccaagtactg cggttcctgc gtggacggcc gatgctgcac gcccagctg accaggactg 1200  
 tgaagatgag gttccgctgc gaagatgggg agacattttc caagaacgct atgatgatcc 1260  
 agtccctgca atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320  
 ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380  
 cctagacaaa caaggagaa gagtgtcaga atcagaatca tcgagaaaaa gggcggggg 1440  
 45 ggtgtgggtg atgggactca ttgtagaaa gaagccttgc tcattcttga ggagcattaa 1500  
 ggtattttcg aactgccaag ggtgtgtgtg cggatggaca ctaatgcagc cagcattgga 1560  
 gaatactttg cttcatagta ttggagcaca tgttactgct tcattttgga gcttgtggag 1620  
 ttgatgactt tctgttttct gtttgtaaat tatttgcata gcatattttc tctaggcttt 1680  
 ttctcttttg gggttctaca gtcgtaaaag agataataag attagtggga cagtttaag 1740  
 cttttattcg tcccttgaca aaagtaaatg ggagggcatt ccatcccttc ctgaaggggg 1800  
 50 aactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860  
 ggtgttttaa gactgaatgt tttatttatc aaaatgtagc ttttggggag ggaggggaaa 1920  
 tgaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980  
 tatggaaatc accatttaat aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040  
 tatttttaga ggtgtcccaa agtcattagg acaaacctag ctcacgtact caattattca 2100  
 aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160  
 55 ttataccttc agtagagaaa agtctttgca tataaagtaa tgtttaaaaa acatgtattg 2220  
 aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56  
 <211> 1636  
 <212> DNA  
 <213> Human

5

<400> 56

cttgaatgaa gctgacacca agaaccgagg gaagagcttg ggcccaaagc aggaaaggga 60  
 agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120  
 10 cagtttgatt ggaagtcag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180  
 tggtttgctt ggtctcaagg acactgcatc gtcaaaactga tccccctggcc gttggaggag 240  
 cagttcatcc ctaaaagggt tgaagccaaa agccgaagta gcaaaaatga gacgaaagg 300  
 cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360  
 agcccgtagc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtgcc 420  
 gatgtctctt gcctggttct tgcacggga ctcaacgatg ggcagatcaa gatctggag 480  
 15 gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540  
 agcttcacac ccagtggcag tttgattttg gtctccgctg caccggataa gactcttcgc 600  
 atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660  
 gtttactgct gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720  
 tcggtctttc tatggagcat gaggctctac acgttaattc ggaagctaga gggccatcaa 780  
 agcagtgttg tctcttgta ctctcccc gactctgccc tgcctgtcac ggcttcttac 840  
 20 gataccaatg tgattatgtg ggaacccctac accggcgaaa ggctgaggtc actccaccac 900  
 acccagggtt accccgccat ggaagacagt gacgtccaca ttagctcact gagatctgtg 960  
 tgcttctctc cagaaggctt gtaccttgcc acgggtggcag atgacagact cctcaggatc 1020  
 tgggcccttg aactgaaaac tcccattgca ttgtctccta tgaccaatgg gctttgtctg 1080  
 acattttttc cacatggtgg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140  
 tggacagctc ctagggtcct gtccctcactg aagcacttat gccggaaaagc ccttcgaagt 1200  
 25 ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcttc 1260  
 acatacagga ctttttaagc aacaccacat ctgtgtcttc tttgtagcag ggtaaaatcg 1320  
 cctgtcaaag ggagtgtctg gaataatggg ccaaacatct ggtcttgcac tgaatatgca 1380  
 tttcttttgg attgtgaata gaattgtagc aaaccagatt ccagtgtaca taaaagaatt 1440  
 tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500  
 aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560  
 30 aagatggtga aggtgaggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620  
 gaccctgtgc tgcgtt

<210> 57  
 <211> 460  
 <212> DNA  
 <213> Human

35

<400> 57

ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60  
 gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa cacaaaagaa 120  
 40 tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgcagcaggg 180  
 ggaggagacc cagcaaggga gcctccattc ccaggactct ggaggggagc gagaccatcc 240  
 atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg cagggtggga 300  
 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aacccaacca 360  
 gcctcctaga ccacggtctc tcccatcaat ggaatgctag agactccagc cagggtggga 420  
 ccgagctcga attcgtaatc atggctcatg ctgtttcctg

45

<210> 58  
 <211> 1049  
 <212> DNA  
 <213> Human

50

<400> 58

atctgatcaa gaataccctgc cctgggtcact ctgcggatgt ttctgtccac ttgttcacat 60  
 tgaggaccaaa gatattcttt ttacagagg cactgtgtcg gtctaacaca gacacctcca 120  
 tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctcccca gcctcgacta 180  
 cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240  
 55 gtgaggtct ctgcaagggt taccgtggct ctgcattcct caggcattaa aggtcttttg 300  
 ggatctacaa ttttgtagag ttttccattg tagtctgag tcatactttt actgcttgat 360

EP 1 166 799 A1

5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55

```

aaaatgtaaa cttcacctag ttcattttct ccaaattccca agatgtgacc ggaaaagtag 420
cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
ggacttttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
aatctttctg actggcagcc ccggtataca aatccacca ccaaggacc attactgaat 600
ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccccttat tatctgtaga 660
attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
aacacttcgg ggggctggtt ggtgctggtt aagtctgggt tgctccttg tatggaataa 840
ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
acttcaagaa agactctggc tgttctcaa

```

<210> 59  
 <211> 747  
 <212> DNA  
 <213> Human

<400> 59

20  
 25  
 30  
 35  
 40  
 45  
 50  
 55

```

tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
ccttaattta caaagcctca gtcattcata cacattagg gatccacagt gttcaaggaa 120
cttaaatata atgtatcata ccaaccacag taaaccaagt acaaaaaata ttcatataaa 180
gttgttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
aaagaagccc ctggcacaaa agattccagt gcccctgaag aggetccctt cctcctgtgg 420
gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
ccctcgggca ggcaacggca gtggactcat ctgggtgatg gctgtagatg ctaacactgg 540
ccaattcaat gccacaccta ctggttacct tttaggggca tttctccaga cagaagcccc 600
ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
gccagtagc acatgcttgc agaagttaga tctctggact tctgcctcca gtcgaccggc 720
cgcgaattca gtagtaatag cggccgc

```

## Sequenzprotokoll

5 <110> Schering Aktiengesellschaft

<120> Menschliche Nukleinsäuresequenzen aus homo sapiensen Endothelzellen

<130> 51867AEPM1XX00-P

10 <140>  
<141>

<160> 60

15 <210> 1  
<211> 1835  
<212> DNA  
<213> homo sapiens

<400> 1

20 ttttacagtt ttccttttct tcagagttta ttttgaattt tcattttttg ataaccaagc 60  
agctctttaa gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120  
tttctttttt tttttttaa tttttttaat agtcacattc agctcgcttg ctcaaaccag 180  
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240  
tatacaaaac gccaaaaaac cataatggtg ccacagggat ggagcaggga agggcatctc 300  
25 taacgtgtcc tctagtctat cttecgctaaa cagaacccac gttacacatg ataactagag 360  
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420  
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaagggtt 480  
aagaaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540  
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600  
attaaaaggc ttggatgtta agagaggaca ctacgcggtt cctgaaggga gacgctgaga 660  
30 tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720  
catttaagcg acaacaaaaa aaggcaaac ccaaaacgca acctaacca agcaaaatct 780  
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcataacct 840  
gagacgctac gtgccaacct aagtctctaa cgacagcttc acagtaggat tatttgtata 900  
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960  
gtgatcgta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcgatac 1020  
35 gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080  
tccgccaaag tcatecttta ttccgagtaa taactttaat tcctttctaa catttacag 1140  
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgce gttccgtttc 1200  
ctccacgaac ggttacgcgc ttccatgaga aaggatattt ggcaatttta tattccacag 1260  
tcaggtgggt ctgcgatagc tcatttaatg ttaaagccca tcaggggcct ctctcccg 1320  
ttctgccagg ggtctttctt gtctctctct tggcgagctc gtgggcagat ctctctgg 1380  
40 gggggctggc tgctggctcc gagggggcat ccgcagtcct tctggctgct tctctctgca 1440  
ggctgggcag ctggccacca ctctccgac tcgaccctc caacaagcat cgcagggcac 1500  
tgtctcggg ggtacagacc gtgtcccac attcgtacc actctgttcc acgtcatcca 1560  
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggtctcttc tgctggtgct 1620  
cttgacggg cggttagttc tgctgcagag aaaaagcatc tccccttccc ttccgggctg 1680  
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740  
45 cagctctttg gagaatcaat gtatgaatgt ctaacctgac cggttgacct gccatccaag 1800  
gagacgaacc acgcccgggg gtgcggaagc ggcct

<210> 2  
<211> 581  
<212> DNA  
50 <213> homo sapiens

<400> 2

55 gttctagatt gttttattca gtaattagct cttaagaccc ctggggcctg tgctaccag 60  
acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120  
tcaacttact tctctgtggc cattagggaa gtggtgacct cgggagctat ttgcctgtt 180

EP 1 166 799 A1

agtgcacaca cctggaacaa tactgctctc attttttcat ccacatcagt gagaaatgag 240  
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360  
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420  
 5 aaatgtcaag ctttgactga aaactcccgt tttccagtc actggagtgt gtgcgtatga 480  
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540  
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g  
  
 <210> 3  
 <211> 516  
 10 <212> DNA  
 <213> homo sapiens  
  
 <400> 3  
  
 tagagatgtt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60  
 15 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcg aacctgaatg 120  
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180  
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240  
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
 tctcgcgcat tgcaggctctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360  
 atgaactgga tgaggaaagg ctctattgca acagtgtctt ggcccagcag tgcataca 420  
 20 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480  
 atgaagttcc agagtgtgt gtgtaaagt cgtctg  
  
 <210> 4  
 <211> 1099  
 <212> DNA  
 25 <213> homo sapiens  
  
 <400> 4  
  
 cccacaacac aggggcccctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60  
 30 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120  
 ccacggggag gtagaagaag acctgggtccg tgaagggtc tgagaagggt ccctgggtcg 180  
 ggggtgcgtc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240  
 gcaccaactc cagcagggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300  
 tgaagatggt cttctccgtg gggcgagaga caaagcagtc caccaggtag gggcagggtg 360  
 ctgctggca cacaacacag ggctccatgg tccagccgta caggcgccac tggccataga 420  
 35 ggaagcctgc ctctagcaca ctcttgacaga gcacactggc gacatagggt cccatcagt 480  
 ctccgcgat ggcagggcga ccattctctg ccaccgagat cttggccatc tgacgctcta 540  
 cgcccgccag cgcccgtctc acctgtgggt ccttggcccg cagtggccgc agctccccct 600  
 ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660  
 ggggtgggtg gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720  
 aggcctggtc atagcagacg ttgggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780  
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840  
 40 agagcaccgt cagccagatc ttaccacca cggtcgagtg ctctggacc tggccagca 900  
 acttctccac gaagccccag taccatgg ctcccgggcc tccgtcggca aggagacaga 960  
 gcacgtcagt gtgtcagcat ggcattcttc tcgttcgccc agcaacaagc ctgcaggag 1020  
 gtctgccacg cccgttctac cgctgcctg ccggcgccg cagggtggag tggggacgat 1080  
 ggccggagtg acgcccgcg  
  
 <210> 5  
 <211> 1015  
 <212> DNA  
 45 <213> homo sapiens  
  
 <400> 5  
  
 gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60  
 50 aaaaagtgtc ttttgaatat gttgaggttg aaatgatggg aaccaacatt ctttgattt 120  
 agtggggagc ataatagcaa acaccccctt ggttcgcaca tgtacaggaa tgggaccag 180  
 ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagt gggccagggc 240  
 ccagacccaa gaggagaggg tgggtccgag acaccccggg atgtcagcat ccccgacct 300  
 55 gccttctggc ggcacctccc ggggtgctgt ttgagtcagc aggcattggg tgagagcctg 360



EP 1 166 799 A1

gtatatgctg ggaacagggg gcagggggcca agcggttctc cttcagcctt gacttggggcc 420  
 atgcaccccc tctcccccac acacaaacaa gcactttctc agtatggtgc caggacaggt 480  
 gtcctctcag tctcttggtt atgacctcaa gtccacttg ggccctgcag cccagcctgt 540  
 gttgtaacct ctgcgtctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600  
 5 atcatcattg ttgctttatc acttctaaga cttttgtac ggacacggaca agttaaacag 660  
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720  
 ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780  
 gagcctagag caggaggtcc cgaacttctg catcacaga ccacctccac aattgttata 840  
 accaaaggcc tctgttctg ttatttctact taaatcaaca tgctattttg ttttctactca 900  
 10 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcagtgtca cgtgctagt 960  
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

<210> 6  
 <211> 2313  
 <212> DNA  
 <213> homo sapiens

15  
 <400> 6

ccagagcagg cctggtggtg agcagggagc gtgcaccgga cggcgggagc gagcaaatgg 60  
 gtctggccat ggaacacgga ggggtctacg ctcgggcggg gggcagctct cggggctgct 120  
 20 ggtattacct gcgctacttc ttctctctcg tctccctcat ccaattcctc atcatcctgg 180  
 ggctcgtgct cttcatggct tatggcaacg tgcacgtgag cacagagtcc aacctgcagg 240  
 ccaccgagcg ccgagccgag ggcctataca gtccagctct agggctcacg gcctcccagt 300  
 ccaacttgac caaggagctc aacttcacca cccgcggcaa ggatgccatc atgcagatgt 360  
 ggctgaatgc tcgcccgcgac ctggaccgca tcaatgccag cttccgccag tgccagggtg 420  
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480  
 25 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcatgtctga 540  
 atcagaaggt gaagagcgtg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600  
 ataaggaaaag cgtgctgctg aacaaacgag tggcggagga acagctggtt gaatgctgga 660  
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaaggtgca 720  
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780  
 ggactccatt atcccacgca gcagagcctg cgaccacatg cccagcctca tgagctccaa 900  
 30 ctcggaattg gcctccatcc gcctccgggc ggatatcgaa cgcgtggccc gcgagaactc 960  
 ggtggaggag ctgcccggga tggaaagcca gcagggcctg cgggccaagt aggaggcgaa 1020  
 agacctcaa cgccagaagc ctacaggccg ggaggccaag ctccaagtgc aatgctccc 1080  
 gcagaccag ctgagcgtgg aggagaaggc ggtgctgcgg aaggaaacgag acaacctggc 1140  
 caaggagctg gaagagaaga agagggaggg ggagcagctc aggatggagc tggccatcag 1200  
 35 aaactcagcc ctggacacct gcatcaagac caagtgcag ccgatgatgc cagtgtcaag 1260  
 gccctgggc cctgtcccca acccccagcc catcgaccca gctagcctgg aggagttcaa 1320  
 gaggaagatc ctggagctcc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380  
 ctgaggaggg tccaggcctg aggaaccaag gatggcccga ctgcggcggt tgcggaggat 1440  
 gcagggatat gctcacagcg cccgacacaa cccctcccgc ccgcccccaa ccaccaggg 1500  
 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcacccgag 1560  
 40 cctcacgac cctcacccag agcacacggc cgcggagatg acgtcacgca agcaacggcg 1620  
 ctgacgtcac atatcaccgt ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680  
 tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740  
 acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800  
 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagt 1860  
 acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920  
 45 ccctttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgacctggg 1980  
 acacgggcca aggtacccac aggtacccat cccctcccgc acagccctgg gcccagcac 2040  
 ctcccctcct ccagcttctt ggctcccag ccaactctct acccccagtg cctggaccgg 2100  
 gaggtgagaa caggaaagcca ttacactccg ctcttgagc gtgagtgttt ccaggacccc 2160  
 ctcgggggccc tgagccgggg gtgagggtca cctgttgtcg ggaggggagc cactccttct 2220  
 cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280  
 50 agtaaatcct taaaaaaaaa aaaaaaaaaa aaa

<210> 7  
 <211> 389  
 <212> DNA  
 <213> homo sapiens

55  
 <400> 7

EP 1 166 799 A1

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc ttttaggctat 60  
 gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccctgc 120  
 tattctaaaa tcagatcctt acagatccag atttcaggaa acaatacat aggggactaa 180  
 5 ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240  
 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300  
 gaaccctgag ctattaataa tctatgtggc tagtgcgat atattggtct gaatttgttc 360  
 tccttttgtg gtgtccagtg ggtaacatc  
  
 <210> 8  
 10 <211> 157  
 <212> DNA  
 <213> homo sapiens  
  
 <400> 8  
  
 15 tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60  
 gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120  
 cctcaatctg tgaactatat gtgagtttga tattttg  
  
 <210> 9  
 <211> 561  
 20 <212> DNA  
 <213> homo sapiens  
  
 <400> 9  
  
 25 aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60  
 gatgttgttg gctgacatac aggtctcagc agcagagaaa gaattctgaa tttcccttgc 120  
 tgaactgaac tattctgtta catatgtgtg acaaatctgt gtgttatttc ttttctacct 180  
 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240  
 tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300  
 tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360  
 tcaccactat aaaactgtca attattgcct aatgttaaaag atatccatca ttgtgattaa 420  
 30 ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgatc 480  
 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540  
 ctgccccaat ttctaagaaa a  
  
 <210> 10  
 <211> 1508  
 35 <212> DNA  
 <213> homo sapiens  
  
 <400> 10  
  
 40 cacaacacag agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60  
 tcgcaggtcc attctctctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120  
 gggctcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180  
 ggatcatcct tctctcccg gcctgttgct gatggcataa tccgggtgca acccaaatct 240  
 gagctcaagc caggtgagct taagccactg agcaaggaaag atttgggct gcacgcctac 300  
 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctaccaag gcctctgcca 360  
 tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420  
 45 acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480  
 tgtgtctgac acccatgttc ttgcagccag tctcactgtt gtacacgat gtcagccatg 540  
 ggtgtcatgt cctctttttt gccttggtta tgggtgtacc ttccagccaa gggttgcctt 600  
 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660  
 aacacagttt gctgcaaagt tcccactgtc ccccctagga actttgaaaa accaacaatag 720  
 catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780  
 50 atgcaaccaa ctaaacagtt ataactctgg cactgttaat agaaaagtgg gatagtcttt 840  
 gctgtttgct gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900  
 ctcagctaata ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960  
 ctaaaagcaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaact 1020  
 tgtaaaattag cagatgactt ttttccattg tttctccag agagaatgtg ctatattttt 1080  
 gtatatacaa taatatttgc aactgtgaaa aacaagtgg gccatactac atggcacaga 1140  
 55 caaaaaatat tatactaata tgttgtacat tcggaagaat gtgaatcaat cagtattgtt 1200

EP 1 166 799 A1

5 ttagattgta ttttgcccta cagaaagcct ttattgtaag actctgattt ccctttggac 1260  
 ttcatgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320  
 attgtttagt gtaaaagaata tttatttgaa gttttattat tttataaaaa agaataattta 1380  
 ttttaagagg catcttacaa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440  
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500  
 aaaaaaaa

<210> 11  
 <211> 389  
 <212> DNA  
 10 <213> homo sapiens  
 <400> 11

15 gggcagggtga tcagggcaca catttcccggt ccattgagac agtagcattc ccggcaccca 60  
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccgcac 120  
 aggatgggtg gccacagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180  
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240  
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgta 300  
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360  
 acctcggccg cgaccacgct gggtagcca

20 <210> 12  
 <211> 981  
 <212> DNA  
 <213> homo sapiens

<400> 12

25 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60  
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120  
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180  
 aagacccttt caagcagtaa gctgcatgct tgcttggtgt ggctattaaa aaccctagtt 240  
 taggataaca acatattaat cagggcaaaa tacaatatgt tgatgcttgt tagtagagta 300  
 acctcagaat caaaatggaa cggtttttaca gtgatatcat tatatttcat ttggcagaat 360  
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagt 420  
 taggataaca ggtctgcctg tttgaagatg aaaaataata ccatttataa atttgcccta 480  
 ctaaatcttc ttctcagtca catttttaact tttaaacagc taatcactcc catctacaga 540  
 ttaaggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagtttaaa 600  
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660  
 35 cacacagtggt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720  
 taccaggagc agaaccatta agctggtcca ggcaagttgg actccaccat ttcaacttcc 780  
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840  
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900  
 cactgcatct gcaccacgca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960  
 40 ataagagttc ttttgatgac g

<210> 13  
 <211> 401  
 <212> DNA  
 <213> homo sapiens

45 <400> 13

50 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60  
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggtaggc aacactgccc 120  
 tctctcccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180  
 tccctaccca gcacactctc ttactgcca cctgcaatta tgctgtgaag atgactgggt 240  
 gtggtcatca cgattcagag aaatcaagat ctatgacat tttaggcaaa gagagaaact 300  
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatctc 360  
 acttcagcat atttagttgt cattaaaatt aagctgatat t

<210> 14  
 <211> 1002  
 55 <212> DNA

EP 1 166 799 A1

<213> homo sapiens

<400> 14

```

5   gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
    acagttgtgg agaacaggtt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
    tttgaaaatg ttaaatacaa gtcctattct cttgtccag ctgggttag ctagaggtag 180
    ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
    gaagtaata tctggggccc atgcaccccc cactaagtac tttgtcacca tgttgtatct 300
    taaaagtcat ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
10  ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
    tggctataac cgaatgttaa atcccacttc aaacaacaaa gtttgacaag actgaaatgt 480
    tactgaaaac aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
    tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
    attaatacag ctcaaatgga gtagtaacca agcttttctg cccagggaagt acaaaacatc 660
    actacgaaca tgagagtaca agaggaaaact ttcataatgc attttttcat tcatacattc 720
15  attcaataaa cattagccaa gctaattgtcc caagccactg tgccagggtat taacaatata 780
    acaacaataa aagacacagt ccttcctctc aaggtgttca gtctagtagg gaagatgatt 840
    attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
    gcctatgttc tcagatatcc ttggttaggtc aggagtggga acccaaaatc aattctttta 960
    acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

```

20

<210> 15

<211> 280

<212> DNA

<213> homo sapiens

<400> 15

25

```

    cgagggtggc caccctgtgc tggctctgaga tttttaaatg aggattacat taccctattt 60
    ataataattcc tatttctaate tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
    aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
    aactgtatta tgactctcaa tatttaaaaca tttaaaaaaa tgttagtggt tgtaagcac 240
    caatcttaac tatttcacct gcccgggcgg ccgctcgagg

```

30

<210> 16

<211> 2041

<212> DNA

<213> homo sapiens

35

<400> 16

```

    cccccgcag aactcccccc tgggaatagga tttttaaaac ccttgacaat tagaaatcct 60
    atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
    cttaaaacca attcagcaca tatgtataaa gaacctttt taaaaacatt tgtacttgaa 180
    atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
    aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
    atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
    ttaccttag catcaattct ttataaaga atgctaaata aattacattt tttgttcagt 420
    aaaactgaag atagaccatt taatgtcttc taccaaattt aacgcagctt aattaggagc 480
    caggtagata ttttctctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
    gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
    ataaaaacaa gactgagtg ttttctcttg aagtataagg gtctaataaa aaataaaaaga 660
    tagatatttg ttatagctg acatttttaac agtcatagta tttagcgttt cgtgaccagt 720
    gcatttttga ctctctcagg atcaaaatac gactctgcca actgtattaa atcctcctcc 780
    cccccctcca ccagttgggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
    ccgaaatgaa catgaagcag atgcagcttg gagggcccgg gctcgagcat tcaactcttg 900
    ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttcct tctgtagagg 960
50  tgggtctcca tttatccaga gtccactggt tgggttatta cacttaaac cattagtact 1020
    atgtgtttt ttatacaaaa gcacataaag tgtgtccttt ggaacctgc tcgtaatttt 1080
    ctggactgac tgaatgaag taatgtcac tctactgtca ttaaaataaaa acccattctt 1140
    ttgacatttc ctatttttcc aaatcctgtt caaaaactgc actgggacta tctctccccta 1200
    gtaaatgact ctgggaggat gctaagtcca gagcctcaga ctggtggtac atctgatag 1260
    aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320
55  taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380

```

EP 1 166 799 A1

catcagtcctc tgaaggcttt aatttttttag caaggttctc actaagatca gtgaagtcaa 1440  
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500  
 ccaaaaccag tggccagtga tacattgtct aaaaatttcc ttctcacatg atacttctga 1560  
 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgata 1620  
 5 gttttctcag cattttgcag agaggcacag ttttcacaat aatattgggt atcaccagta 1680  
 agaattctctg gagcccaaaa aataatttag taagtacagt actgaagggt tggtttcacc 1740  
 tcccggtttc tgaggtagat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800  
 agtgttttca gaacagtaaa actcattagg aggactgcct atggtttttt cattcacaag 1860  
 tgagtcacag atgaaggcag ctgttgttgg attataaact actggctctt ctgaaggacc 1920  
 10 gggtagacag gcttgacatta gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980  
 gacagacatg ttttccaaag aagagggaag acaaaacgca agcgaaagat ctgtaaagcg 2040  
 t  
 <210> 17  
 <211> 235  
 <212> DNA  
 15 <213> homo sapiens  
 <400> 17  
 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccctc 60  
 20 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaacaa ctgtagtctc 120  
 agatactcag gagactgagc tggaaaaggat cacttgagcc caagaagttc aagggttacag 180  
 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta  
 <210> 18  
 <211> 2732  
 25 <212> DNA  
 <213> homo sapiens  
 <400> 18  
 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60  
 30 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120  
 aaatattatc ttcttgggtg tcacattgtg caaaatggtg aagcattcaa acactttgaa 180  
 accagattct agcaggttgg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240  
 gtgtcttctt ggctcacctt ggtcctttgg gttgcttttt attaatgagg agactattgt 300  
 gatggcatac ctcttcaacta tatttaattgc ttccaggga gtgttcatat tcatctttca 360  
 ctgtgctctc caaaagaaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420  
 35 ctgtggaggc ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480  
 cagtgtctgc tattcctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540  
 gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600  
 tcaaggtggc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660  
 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagtg 720  
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780  
 40 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840  
 agaaaaatgat catttcagaa ttagtgacac acaacttacg gggcagcagc aagactcaca 900  
 acctcgagct cagcgtacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960  
 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtct gagctccatc 1020  
 acaagaaact cgaggcacca cttattcctc agcggactca ctcccttctg taccaacccc 1080  
 agaagaaaag gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140  
 45 aagatcacct acagtcccc acacagagct ctctttatag aagcatgccc aatcttagag 1200  
 actctcccta tccggagagc agccctgaca tggagaaga cctctctccc tccaggagga 1260  
 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320  
 agatgtgcta ccagatcagc aggggcaata gtgatggta tataatcccc attaaacaaag 1380  
 aaggggtgat tccagaagga gatgttagag aaggacaaat gcagctgggt acaagtcttt 1440  
 aatcacacag ctaaggaatt ccaagggcca catgcgagta ttaataaata aagacacat 1500  
 50 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560  
 tgggtgtaaaa aagatgactg aaccttgtag ttctgtgaat ttttataaaa catacaaaaa 1620  
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaga agagatgcaa 1680  
 gccagggtatt ttaagattct gctgctgttt agagaaattg tgaacaagc aaaacaaaac 1740  
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800  
 tttgtaggcc tgcatgtgat tatatacaag acgtaggctt taaaaatcctg tgggacaaat 1860  
 55 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920  
 tttgcagttc actgcaaact ttttacatta aggcacaaag tgaaaacatg cttaaccact 1980

## EP 1 166 799 A1

5 agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040  
 atgaaaaatg gctaaagaaa ttatatatttg ttctattgct agggtaaaat aaatacattt 2100  
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160  
 aaaagctctt ggttgacat gttatgaaat gtttttctt acactttgtc atggttaagt 2220  
 ctactcattt tcacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280  
 tattacttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340  
 tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400  
 tgtcaccctt gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460  
 tttctagtga acaaaagggt cctattcttt tttaaaaaaa taaaaataaa cataaatatt 2520  
 actcttccat attccttctg cctatatatta gtaattaatt tattttatga taaagttcta 2580  
 10 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640  
 ttaataatga gcccatcact aatatccagt gtaaagttta acacggttg acagtaaata 2700  
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

<210> 19  
 <211> 276  
 15 <212> DNA  
 <213> homo sapiens

<400> 19

20 ctccctaaat gatttttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60  
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120  
 tattccctat atagcaaac aaaaccagga cctcccaact gcatgcctca agtccctgtg 180  
 gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240  
 gggaccaatt aaatacctcg gccgcgacca cgctgg

25 <210> 20  
 <211> 2361  
 <212> DNA  
 <213> homo sapiens

<400> 20

30 attgtaccag ccttgatgaa cgtggggcct gcttcgcttt tgagggccat aagctcattg 60  
 cccactgggt tagaggctac cttatcattg tctcccgtga ccggaagggt tctcccaagt 120  
 cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180  
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttgctg 240  
 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300  
 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360  
 35 ttgccaagag ccagcatctg gacagtgtat ggctggccca gattttcatg cagtatggag 420  
 accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480  
 gaaagtggga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540  
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600  
 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcacaga 660  
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctccggcagg 720  
 40 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcatcatcat gagtgggtacc 780  
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggaagc 840  
 tgccttttga gcaggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900  
 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960  
 aaggccgcag cgataggag gccacaggct gcagggccaa ctctgaggag ttcattccca 1020  
 tctttgccaa taaccgcgca gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080  
 45 cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140  
 acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200  
 gtggtcgctt ctgagacgtc tttgacaagg ccttggtcct gtgccagatg cagcacttcc 1260  
 aggatggtgt cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320  
 acatgcagca cgagcagtac cggcaggtca tcagcgtgtg tgagcgccat ggggagcagg 1380  
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440  
 50 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgccca cctcttctag 1500  
 tgggtgcagac cctggccac aactccacag ccacactctc cgtcatcagg gactacctg 1560  
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcggg 1620  
 accgagagga gaccacccgt atccgccagg agatccaaga gctcaaggcc agtcctaaga 1680  
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgcc tcagtcact 1740  
 55 tectgtgtgg ccactccttc caccaacact gctttgagag ttactcggaa agtgatgctg 1800  
 actgccccac ctgcctcctt gaaaaccgga aggtcatgga tatgatccgg gcccagggaac 1860

EP 1 166 799 A1

5 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920  
ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980  
ctcccacagc cagactgacc tccagcctgg aggcctgggct gcaacgcgac ctactcatgc 2040  
actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100  
agaacagaca caatgggacc tggcgggcg ttacacagaa ggctggctga catgcccagg 2160  
gctccactct catctaattgt cacagccctc acaagactaa agcggaaactt tttcttttcc 2220  
ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280  
ttagaatcat ttccagatta atggggggga aggggaacct caggcaaaccc tcctgaagtt 2340  
ttggaaaaaa aagctgggtt c

10 <210> 21  
<211> 179  
<212> DNA  
<213> homo sapiens

15 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60  
acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc ctggaacagc 120  
tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

20 <210> 22  
<211> 905  
<212> DNA  
<213> homo sapiens

25 <400> 22

tttttttttt ttctttaacc gtgtgggtctt tatttcagtg ccagtgttac agatacaaca 60  
caaatgttcc agttagaagg aattcaaacg gaatgccaaag gtccaagcca ggctcaagaa 120  
ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccctaagg 180  
caaagggtact ttgtatagac agtctgatct ttgaaactgg tgaactcctc ttccacccat 240  
taccatagtt caaacaggca agttatgggc tttaggagcac tttaaaattt gtggtgggaa 300  
taggggtcatt aataactatg aatatactct ttagaagggt accattttgc actttaagg 360  
gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420  
gggagctgga agagccttgg aagtttctat tacaatataga gcaccatata cttcatgcca 480  
aatctcaaca aaagctcttt ttaactccat ctgtccagt tttacaaata aactcgcaag 540  
gtctgaccag ttcttggtta caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600  
cagaaaaggc taccaggagc ctaatgcctc tttcaaactat tgggggaacc agtagaaaaa 660  
ggcagggctc cctaattgtc attattacat ttccattccg aatgccagat gttaaaagt 720  
cctgaagatg gtaacccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780  
aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840  
ccatggattg cagtcctctc ctccagacca gctgcttatt tcctcagggg cccagggaat 900  
gttga

40 <210> 23  
<211> 2134  
<212> DNA  
<213> homo sapiens

45 <400> 23

ggctctcttct ttcttttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60  
gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120  
cattagaaat aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180  
tccttcttgg aaggaaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240  
tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300  
accaggatac gactgttgga ccagctgctg gagatggacc tgctacccct cagcagcctc 360  
cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420  
tcatttttgt tccggcggtt catcctctct gtgtgattgt actgattttc atgagacaca 480  
agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaaat 540  
tggagggtact aagctcattg tgtctctctc agcttttacc agcatctaatt gcttactgc 600  
tttttttcca ttgtagactt taatgcactt gaataaatac atggagtgtt tttttctca 660  
aaatgaatta cacaataaaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720  
gttatttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780

EP 1 166 799 A1

tagaaataat gtataaacat tctctgaac catagcagcc ataaacagtg ctgggtcaaag 840  
 atcctatttg tactcctttc tccccccatt gttagttagg taaagtaaaa cagggtccttag 900  
 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960  
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttggtttt 1020  
 5 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080  
 tgctatatca ctgctcagag gttaataatc ctactaact atcctatcaa atttgcaact 1140  
 ggcagtttac tctgatgatt caactccttt tctatctacc cccataatcc cacccttactg 1200  
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260  
 gcaccagccc ttctcactt tgctttgccc tcaaagctaa caccacttaa accacttaac 1320  
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaa ggatcacagc 1380  
 10 tctcatgaga taacacccct ccactatggg acagacactt caagcttctt tttttgtaac 1440  
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggt 1500  
 ggtctgcaca aggtctgggt ctggctggct tcaacttctt tgcacactcg gaagcaggct 1560  
 gtccattaat gtctcgccat tctaccagtc ttctctgcca acccaattca catgacttag 1620  
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680  
 taatttttagg tcgaagggca tgcccacag 1740  
 15 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800  
 ccgcagagga gccgctgtac ctcaagacaa cacttttgta cataatgtct tgctctaagg 1860  
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920  
 agctgccatt gttcctggat cccctctggt tccgctgttt cacttcgatg ttggtggctc 1980  
 cagttggaat tgtgatgata tcatgatatc cagggttttg actagtaact gatcctgata 2040  
 20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttg 2100  
 agtctatgat gcgatcacia ccagctttta caca

<210> 24  
 <211> 1626  
 <212> DNA  
 <213> homo sapiens

25  
 <400> 24

ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60  
 ttattttgaa tacagacatt ggctccaaat ttcatcttt gcacaatagt atgacttttc 120  
 30 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gttaaggctg 180  
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacagggt gaacaaacgt 240  
 agttgttttt tactgatact aaatgttgcc tacctgtgat tttatagtat gcacatgtca 300  
 gaaaaaggca agacaaatgg cctctgtgac tgaatacttc ggcaacttta ttgggtcttc 360  
 attttctgac agacaggatt tgactcaata ttgttagagc ttgctgtagaa tggattacat 420  
 ggtagtgtg cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480  
 35 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggttttag 540  
 aaagctttgt ctaaaaaattt ggcctaggaa tggttaacttc attttcagtt gccaaagggt 600  
 agaaaaataa tatgtgtgtt gttagtttta tgtaacata ttattaggta ctatctatga 660  
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720  
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780  
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840  
 40 tctggaatgc attagttatg ccttgtacca ttcccagaat ttcaggggca tctgtgggtt 900  
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960  
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020  
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080  
 taaaattcct aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140  
 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200  
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260  
 45 atggattctt ctatagctaa atgagtccc tctggggaga gttctggtac tgcaatcaca 1320  
 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380  
 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440  
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500  
 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatatat 1560  
 50 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620  
 aaaaaa

<210> 25  
 <211> 1420  
 <212> DNA  
 <213> homo sapiens

55



&lt;400&gt; 25

5 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60  
 ttcatgaaa tccttgctac ttctcttcct cctcaatgaa agacacgaga gacaagagcg 120  
 acacaagctt aagaaaaacg agcaagggaag agtatcttca ttattctcat ttctctgag 180  
 ttggaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240  
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300  
 tccttgctact gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360  
 tattttataa ggcccataaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420  
 10 atggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 480  
 ttaatgctta aaattatata taaaatgctt tatttagaaa acctacatga tacagtgggtg 540  
 tcagccttgc catgtatcag ttctcacttga aatttgagac caattaaatt tcaactgttt 600  
 aggggtggaga aagagggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660  
 atccttttga tgggaggaga gttactcttg aaaggcaggg agcttaagtg gacaatgttt 720  
 tgatatagtg tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780  
 15 tttgctctgt tttgctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840  
 accagtacct ggggagggtta gatgtgtgtt tcaggccttg agtgatgag tggttttgct 900  
 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960  
 gtggctttgt ttttttttct caagtaaaat tgtgaacata ttctctttat aggggcaggg 1020  
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080  
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140  
 20 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200  
 tatagaaatt ttttatactg attggttcat agatggtcag tttgtacac agactgaaca 1260  
 atacagcact ttgccaaaaa tgagtgtagc attgtttaaa cattgtgtgt taacacctgt 1320  
 tctttgtaat tgggtgtgtg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380  
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

25 <210> 26  
 <211> 689  
 <212> DNA  
 <213> homo sapiens

&lt;400&gt; 26

30 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60  
 caaacaatta tagcacatcc ttctttttac tctgtctcac ctcccttagg tgagtacttc 120  
 cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggtag ccttgcccta 180  
 ggtaatcagc ctagtttaca ctgtttccag ggagtagttg aattactata aaccattagc 240  
 cacttgcttc tgcaccatct atcacaccag gacagggctc ctcaacctgg gcgctactgt 300  
 35 catattggggc caggtgattc ttctttgcaa gggctgtcct gtacctgccc gggcgccgcg 360  
 tcgaagcgtg gtcgcgcccg aggtactgaa aggaccaagg agctctggct gccctcagga 420  
 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctc cactattcag 480  
 gaggtggtcg gaggtaacgc agcttcattt cgtccagtc tttccagtat ttaaagtgt 540  
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600  
 40 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660  
 cacaccaga gcctgaagtt tgtccttcg

<210> 27  
 <211> 471  
 <212> DNA  
 <213> homo sapiens

&lt;400&gt; 27

50 tcccagcggc atgaagtttg agattggcca ggcctgtac ctgggcttca tctccttcgt 60  
 ccctctcgct cattgggtggc accctgcttt gcctgtctcg ccaggacgag gcaccctaca 120  
 agccctaacc caggccccgc ccagggccac cagcaccact gcaaacaccg cacctgccta 180  
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240  
 gggtagcaggc tgaacgacta cgtgtgagtc ccacagcct gcttctcccc tgggctgctg 300  
 tgggctggtt cccggcgagg ctgtcaatgg aggcaggggt tccagcacia agtttacttc 360  
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420  
 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

55 <210> 28  
 <211> 929

## EP 1 166 799 A1

<212> DNA  
<213> homo sapiens

<400> 28

5

10

15

20

```

ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
gctgcttctg acggtttggc tgctgggtgg ctttcccctc actgtcattg gaggcattct 120
tggaagaagc aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgccggga 180
gattccaccc cagccctggg acaagtctac tgtcatccac atgactgttg gaggcttcc 240
gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgtcga gtgtgggggc 360
ttgcatctcc attgactca cctacttcca gttgtctggg gaggattacc gctgggtgtg 420
gcgactctgt ctgagtgttg gctccaccgg cctcttcac ttcctctact cagttttcta 480
ttatgcccgg cgctccaaca tgtctggggc agtacagaca gtagagtctt tcggctactc 540
cttactcact ggttatgtct tcttctcat gctgggcacc atctcctttt tttcttccct 600
aaagtctatc cggtatatct atgttaacct caagatggac tgagtctgt atggcagaac 660
tattgctgtt ctctcccttt ctctcatgcc tgttgaactc tcctaccagc tttcttctg 720
attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg catctctcc 780
ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840
taagttgcct taagttttgg tctgtatttt tctttttaca attaccaaaa taaaatttat 900
taagaaaaag aaaaaaaaaa aaaaaaaaaa

```

<210> 29  
<211> 1775  
<212> DNA  
<213> homo sapiens

<400> 29

25

30

35

40

45

50

```

gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
accagaaaaa gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120
ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180
cgcccgctgt gccttctcct cgtaggactc ccctccaggg ccttccaggg cagatgtgcc 240
aggataaagc caccgctggg acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
cagccgggtg gacgtgggca tgggtgatgat gaaggcaaaag acgtcatcaa tgaaggtgtt 360
gaaagccctt tagtgaaagg ccttccaggg cagatgtgcc actgacttca acttgtagt 420
cacaaagagc tggggcagca tgaagaggaa accaaaggca tagaccccggt tgacgaagct 480
gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
cccagacacg agagggtaca gcaggatga caagtacttc atggcctgag tatcgtactc 600
ctcgggtttc ctctcagatt cgctgttaagt gccaaactga aattcgggca tcaggcctct 660
ccaaaaata gtcattctca atgccttctt cactttccac agctcaatgg cggctccaac 720
accgcgggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaac gaaagatgac 780
cacggtgtct aagcagcgcc agagcactgc cttgggtggac atgccgatca tgctcttctt 840
cttcttccag aactctgatg cattttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
tgcgacaaag aaggtcagcg ccaggaagta taagttggta tctacaaaaa ttcctttcac 960
ctcatcagca tcttctctgt aaaaccggaa ctgctgcagg gagtacacgg cgtcctgcat 1020
gtggatccag aagcgcagcc gcccagtgga gaccttgtcg taggacacgg tgagggggcag 1080
ctcgggtgtg gagcggttta tgaccatcag gtccttcacg cggttgctga gctggtcgat 1140
gaacaggatg ggcaggtaat gcacggtttt ccccagctgg atcatcttca tgtaccgatg 1200
cacatcgcca ggcaggagg acccgtcaaa gacaaagttg tccgccatca cgttcagcgc 1260
cagccgcggg cgcagtgagg aactggctc atccagggca ctcgtcggct tcttctccgc 1320
ctcgatctgc tgtgtatcag actcccggg gagcaggttg atttctctg gcttggggac 1380
catgtaggtg gtcagaggac tgaccaggtg cacctgcttc ccgtcgtgcc acggcaggac 1440
cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgttctctg tttcttttgg 1500
tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
gaccaggtcg atgttgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620
ctgcagcttg ggcgcgcgc ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
gcgggtgtag acgatgccgt acatgacca gcagggtgtg accacgtaga ccacgaacac 1740
gcccaccacc aagctggtga aggagctgcg gcccc

```

<210> 30  
<211> 1546  
<212> DNA  
<213> homo sapiens

55

EP 1 166 799 A1

<400> 30

```

aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgcta 60
5  aaggccctgc caggctggga ggggaattgtc cctgcctgct tctggagaaa gaagatattg 120
   acaccatcta cgggcacccat ggaactgctt caagtgacca ttctttttct tctgccaggt 180
   atttgacgca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttgttact 240
   acaacaaaac catctataac aacacaaaac acagaatcat tacagaaaaa tgttgtcaca 300
   ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360
10  atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420
   gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480
   gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaca 540
   acagaaatac caggtagtgt tctacaacca gatgcatcac cttctaaaac tggtagatta 600
   acctcaatac cagttacaat tccagaaaac acctcacagt ctcaagtaat aggcactgag 660
   ggtggaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tattttgccg 720
15  gtggttattg ctttgattgt aataacactt tcagtatttg ttctggtggg tttgtaccga 780
   atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840
   aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900
   gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcataaat 960
   tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
   aatcccgcact tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080
20  tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tcctgttctc 1140
   tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaattttag 1200
   gaggagaatt tgtgagcagt gaatctgaca gcccaggagg tgggctcgct gataggcatg 1260
   actttcctta atgtttaaag ttttccgggc caagaatttt tatccatgaa gactttccta 1320
   cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380
   gcagggaaaa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440
25  gtacatataa gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500
   aatactctaa aaatactata acatgactgt gaaaatggca aaaaaa

```

<210> 31

<211> 750

<212> DNA

<213> homo sapiens

<400> 31

```

cacttgggca cccccatttt ctaaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60
35  aagggaagtg cctctgatgg cccaaaaaac ttcttccaaa ctagtgtagg aatggaatgg 120
   atagcaaatg gatccttttt ggccctcctt ggagcatgcc ttccctatct tatecttgcc 180
   ccactaaaag cagaacgtta cggatatctt tgtttttgcc attggatgcc tatctggcca 240
   aacagccttt ccctaattgg aaaatgcagt cctgtttaaa acctttgatt tacgactact 300
   tgtacatgct tgctcattac aattttgaca ttttttacct agtgaagacc ccaaacatat 360
   cagtgaatac tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420
40  gtggcaagcc aaatttgaaa tatctcattt aaaactcaga cccaattcac tgagtataac 480
   ttttaatagc ttctcagca cactatttcc catgcattaa atatgataaa ataactctac 540
   actgcccatac ggtcttgtaa aaaggaagtc tgaatacaga gccacacaca ctaaaattgt 600
   ttttctagct acaaagtata gcatcatcaa cacagacacg atttggactc cctgacaggt 660
   ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720
   ccaaaggcct tatttgtcac caccgtcccg

```

<210> 32

<211> 1620

<212> DNA

<213> homo sapiens

<400> 32

```

gcaattcccc cctcccaacta aacgactccc agtaattatg tttacaaccc attggatgca 60
50  gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgtccttttt ggtaccaaac 120
   ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180
   atctgtgcaa actctgatga tacctgcctt atgtggattc ttttccacac tgctttcatt 240
   ttttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300
55  atgttctggg ttttttcctt ctttttagaa ccccgctccc atttaaaaaa ttaaaaaaaa 360
   aaaaaaaact ttttaacattt aaaaaataaa aattaacaaa atttcactta ttccaggaca 420

```

cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480  
 tccataattt tcacacaata acagtcacct tctatccagc ttgccttcca tttatctcta 540  
 gggtagcttt ttcaggcaac atccttggtc attgccaga aagtaacctga gctatcagtg 600  
 5 attggaatgg cacaggaaac cgaatcacat gggtgccctc cccttggttt tcaagtatct 660  
 tggagttgtg cacaaaaatt aggtcatgcc ttcagtgtct tgttctttaa acctaccctt 720  
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaatgt 780  
 gtgttcctcc taggttggaa gaaatgtcct tccttctatc tgggtcctgt taaagcgggt 840  
 gtcagttgtg tcttttcacc tcgattttgt aattaataga attgggggga gaggaatga 900  
 tgaatgcaat taagtttcag gtttggcatg atcatcattc tcgatgatat tctcactttg 960  
 10 tcgcaaactc gcccttatcg taagaacaag tttcagaatt tccctccac tatacgactc 1020  
 cagtattatg tttacaatcc attggatgag tgcagcatga taagaccttg gtgccagaa 1080  
 aaatctgtcc tttttgtac caaacctgag gtcttttga agataatga gaaaaccact 1140  
 acctattgaa ggctgtttt ggctaactct tgcaaaactc gatgatacct gcttatgttg 1200  
 attcttttcc acactgcttt catttttaag tataaagact tagaaaacta gaataatgct 1260  
 tttacaaata attaaagta tgtgatgttc tgggtttttt ccttctttt agaaccctgt 1320  
 15 atttaacaaa gccttctttt taagtcttgt ttgaaatga agtctcagat cttctggata 1380  
 ccaaatcaaa aaccaaacgc gtaaaacagc gcagtatttg tgttcctaatt ttaaaaaagc 1440  
 tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500  
 acatacagca ttgtacatta caatgaaaat gtgtaaccta agggatttat atatataaat 1560  
 acatatatac ctttgaatcc tttatactgt aaataaaaaa gttgctttag tcaaaaaaaa 1620  
  
 <210> 33  
 <211> 2968  
 <212> DNA  
 <213> homo sapiens  
  
 <400> 33  
  
 25 gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60  
 gagggaggag aagggaaga agaagatgaa gaaagtgaag agggaggaga agaggaggga 120  
 gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgtcagatga gaaggattca 180  
 ggaagacatc tagataaaaa gccaaagtaa gaaatgagct cagattctga atatgactct 240  
 30 gatgatgacg gacctaagaa agaaagggtc tatgacaaaag caaaacggag gattgagaaa 300  
 cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360  
 gtacttgggc atgtggacac aggggaagaca aaaattctag ataagctccg tcacacacat 420  
 gtacaagatg gtgaagcagg tggatcaca caacaaattg gggccaccaa tgttctctt 480  
 gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540  
 ccagggaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600  
 ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg ttggagccc 660  
 35 cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgactc 720  
 aataagattg ataggttata ttgagtgaaa aagagtcctg actctgatgt ggctgctact 780  
 ttaagaagc agaaaaagaa tacaaaagat gaatttgagg agcgagcaaa ggctattatt 840  
 gtagaatttg cacagcaggg tttgaatgct gctttgtttt atgagaataa agatccccgc 900  
 acttttgtgt ctttgggtacc tacctctgca catactgggt atggcatggg aagtctgatc 960  
 taccttcttg tagagttaac tcagaccatg ttgagcaaga gacttgcaac ctgtgaagag 1020  
 40 ctgagagcac aggtgatgga ggtaaaagct ctcccgggga tgggcaccac tatagatgtc 1080  
 atccttgatca atgggcgttt gaaggaagga gatacaatca ttgttcctgg agtagaaggg 1140  
 cccattgtaa ctgagattcg aggcctctctg ttacctctc ctatgaagga attacgagtg 1200  
 aagaaccagt atgaaaagca taaagaagta gaagcagctc agggggtaaa gattcttgga 1260  
 aaagacctgg agaaaacatt ggctgggtta cccctccttg tggcttataa agaagatgaa 1320  
 atccctgttc ttaaaagatga attgatccat gagttaaagc agacactaaa tgctatcaaa 1380  
 45 ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440  
 gaatttctga aaacatcaga agtgccctat gcagggaatta acattggccc agtgcataaa 1500  
 aaagatgcta tgaaggcttc agtgatgttg gaacatgacc ctgagatgc agtaattttg 1560  
 gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatagttt aggagttaga 1620  
 atttttagtg cagaaattat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680  
 tacaagaaac agaaacaaga agaatttaag cacatagcag tatttcctg caagataaaa 1740  
 50 atcctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacgggtgaa 1800  
 gcaggtcagg tgaacaggg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860  
 ggaatagtaa caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920  
 gaagttttgtg taaaaataga acctatccct ggtgagtcac ccaaaatggt tgggaagacat 1980  
 tttgaagcta cagatattct tgttagtaag atcagccggc agtccattga tgcactcaaa 2040  
 gactggttca gagatgaaat gcagaagagt gactggcagc ttattgtgga gctgaagaaa 2100  
 55 gtatttgaaa tcactcaatt ttttcacatg gagcaggaac tggagtaaat gcaatactgt 2160  
 gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220

## EP 1 166 799 A1

5 gacttaagta tggaaaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280  
 aacttacact gggttgacag tgggtcagtta catgtcccca cagttccaat gtgcctgttc 2340  
 actcacctct cccctcccca acccttctct acttggctgc tgttttaaag tttgcccttc 2400  
 cccaaatttg gatttttatt acagatctaa agctctttcg attttatact gattaaatca 2460  
 gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttgg gacttttttg 2520  
 acgtaagaaa tacttcttta tttatgcata ttcttccac agtgattttt ccagcattct 2580  
 tctgccatat gccttttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640  
 agctgctttg tgtgaaacca tgggttaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700  
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760  
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820  
 10 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880  
 ggtagccag caccgtggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940  
 tgatcggtt agtagagatt ttatacat

<210> 34  
 <211> 6011  
 15 <212> DNA  
 <213> homo sapiens  
 <400> 34

20

25 acggggcgcc ggacgacccg cacatcttat cctccacgcc ccactcgac tcggagcggg 60  
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120  
 cggttgagc cgagcgagc acccccgcg ccccgccca gaagtttggt tgaaccgggc 180  
 tgccgggaga aacttttttc tttttcccc ctctcccggt agagtctctg gaggaggagg 240  
 ggaactcccc cggcccaagg ctctgtgggt cgggtcgcg cggccgcaga aggggcgggg 300  
 tccgcccgcg aggggaggcg ccccgggga cccgagagg gggtagggac cgcgggctgc 360  
 tgggtgcgcg gcggcagcgt gtgccccgcg caggggaggg gccgccccgc tcccggcccg 420  
 gctgcgagga ggaggcgcg gcggcgaggg aggatgtact tggtagcggg ggacaggggg 480  
 ttggccgggt cggggcacct cctgtctctg ctgctggggc tgctgctgct gccgcgcgcg 540  
 30 tccggcaccc gggcgctggt ctgctgccc tgtgacgagt ccaagtgcga ggagcccagg 600  
 aaccgcccgg gtagcatcgt gcaggcgctc tgcggctgct gctacacgtg cgccagccag 660  
 gggaacgaga gctgcggcgg caccctcggg atttacggaa cctgcgaccg ggggctgctg 720  
 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780  
 gaagatgaga actggactga tgaccaactg cttggtttta aacctgcaa tgaaaacctt 840  
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900  
 35 aatccctttg agtttccaag tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960  
 gagaagccag attgtctcaa ggcccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020  
 gattctgttc tgatcgaggg ttatgtcct cctggggagt gctgtccctt acccagccgc 1080  
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140  
 ctagtgtcaa aagcctcagg gaagccggga gagtgcctgt acctctatga gtgcaacca 1200  
 gttttcgcg tgactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260  
 40 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaaca 1320  
 agatgcgagt gtctctctgg cttatgtgggt ttcccctgtg gtgaggtggg atccactccc 1380  
 cgcatagtct ctctgtggca tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440  
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500  
 cgaatggaca actgtcggtt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560  
 cagtgtgggt agataaactc cgagagggtac tacgtgcccg aaggagagtg ctgcccagtg 1620  
 45 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgccaa tggcctgatc 1680  
 cttgcccacg gagaccgggt gcgggaagac gactgcacat tctgccagtg cgtcaacggg 1740  
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800  
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860  
 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920  
 cacaatggtt gtcggacctg tcagtgcata aacaccaggg aactatgttc agaacgtaaa 1980  
 50 caaggtgca ccttgaactg tcccttcggt ttccctactg atgccccaaa ctgtgagatc 2040  
 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100  
 cttggaattg tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160  
 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttctc 2220  
 tgcaagtgca gagaggcctc tgcttcagct gggccaccca tcctgtcggg cacttgtctc 2280  
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340  
 tactgtctca atgtgtgccc ctgatcacct gcccggtgcc tgccctgtggc 2400  
 55 aacccccacca ttcaccctgg acagtgtctg ccatcatgtg cagatgactt tgtggtgcag 2460

EP 1 166 799 A1

5 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520  
 ggagaaacgt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580  
 tgtgagacag aggtgtgccc accgtgtctc tgcagaaacc cctcacgcac ccaggattcc 2640  
 10 tgcctgccac agtgtagaga tcaacctttt cggccttctc tgtcccgcaa taacagcgt 2700  
 cctaattact gcaaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760  
 gacgtttgta ccagctgcat ctgcattgat agcgttaatta gctgtttctc tgagtctctg 2820  
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgtgcc ctactgcata 2880  
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaagcgcta tgccgacgag 2940  
 gagcgggtggg accttgacag ctgcaccacac tgctactgcc tgcagggcca gaccctctgc 3000  
 15 tgcacgctca gctgcccccc tctgcccctgt gttgagccca tcaacgtgga aggaagtgtg 3060  
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120  
 aacctcgaag gagaggttga cctggaggtt ccctgtgtgc ccacgcctag tgaaaatgat 3180  
 atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240  
 caccacaagt aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300  
 tctctctcta ttataatagc attcctattc atcaatcaga agaaaacagt gataccactg 3360  
 20 gcttctgtgt ttcgaacacc aactaagcct tcttctttaa ataacagct agtatctgtg 3420  
 gactgcaaga aaggaaccag agtccaggtg gacagttccc agagaatgct aagaattgca 3480  
 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540  
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600  
 gacgactaaa tctgctctaa aaagttaact agaatttgtg cacttgctta gtggattgta 3660  
 ttggtattgt acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720  
 atgtgcagaa caagcattcc cacttttctc caagataact gaccaagtgt tttcttagaa 3780  
 25 ccaaagtttt taaagtgtct aagatatatt tgcctgtaag atagctgtag agatatttgg 3840  
 ggtggggaca gtgagtttgg atggggaaag ggtgtgttgg gtggtgttgg gaagaaaaat 3900  
 tggctcagctt ggctcgggga gaaacctggt aacataaaaag cagttcagtg gccagaggt 3960  
 tatttttttc ctattgtctc gaagactgca ctggttgctg caaagctcag gcctgaatga 4020  
 gcaggaaaca aaaaaggcct tgcgaccacag ctgccataac caccttagaa ctaccagacg 4080  
 agcacatcag aaccttttga cagccatccc aggtctaaaag ccacaagtgt ctttctata 4140  
 30 cagtcacaac tgcagtaggc agtgaggaaag ccagagaaat gcgatagcgg catttctcta 4200  
 aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260  
 caatcaatca gccagtctct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320  
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380  
 gaacaccagg catttccagg ggctatatatt cactgtttgt tgttgctttg ttctgttata 4440  
 ttgttgggtg ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500  
 35 gactgttttg ggattctttt tctttattat atactgattc tacaaaatag aaactacttc 4560  
 attttaattg tatattattc aagcaccttt gttgaagctc aaaaaaaatg atgcctcttt 4620  
 aaacttttagc aattatagga gtattttatgt aactatctta tgcttcaaaa aacaaaagta 4680  
 tttgtgtgca tgtgtatata atatataat atacatatat atttatacac atacaattta 4740  
 tgttttctct ttgaatgtat ttttatgaga ttttaaccag aacaaaaggca gataaacagg 4800  
 cattccatag cagtgtcttt gatcacttac aaattttttg aataacacaa aatctcattc 4860  
 40 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920  
 gtgtgtgcgc gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980  
 attcctttat taaaatcttc ctcatgttga ttgtcttca gttggttttc aatttgctca 5040  
 ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100  
 tttttttttt tcaaaccaatg gtttgaacaa actactggaa tattgtccac aataagctgg 5160  
 aagtttgttg tagtatgcct caaatataac tgactgtata ctatagtgtt aacttttcaa 5220  
 45 acagccccta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280  
 tgcttgttgt gaaagacaca gataccaggt atgcttaacg tgaaaagaaa atgtgttctg 5340  
 ttttgtaaaag gaactttcaa gtattgttgt aaatacttg acagaggttg ctgaacttta 5400  
 aaaaaaatta atttattatt ataatgacct aatttattaa tctgaagatt aacctatttt 5460  
 ttgtcttaga atatcaaaaa gaaaaagaaa aagggtgtct agctgtttgc atcaaaggaa 5520  
 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaatga 5580  
 50 tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640  
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700  
 caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760  
 ttattatttt aaagatatga tttatcttga gtgctgtatc tattactctt ttactttggg 5820  
 tctgtttgtg ctcttgtaaa agaaaaatat aatttcttga agaataaaaat agatatattg 5880  
 cacttggagt gcatcatagt tctacagttt gtttttgggt tcttcaaaaa agctgtaaga 5940  
 55 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000  
 aaaaaaaaaa a

<210> 35  
 <211> 1036  
 <212> PRT

## EP 1 166 799 A1

&lt;213&gt; homo sapiens

&lt;400&gt; 35

```

5      Met Tyr Leu Val Ala Gly Asp Arg Gly Leu Ala Gly Cys Gly His Leu
      1      5      10      15
      Leu Val Ser Leu Leu Gly Leu Leu Leu Leu Pro Ala Arg Ser Gly Thr
      20      25      30
      Arg Ala Leu Val Cys Leu Pro Cys Asp Glu Ser Lys Cys Glu Glu Pro
      35      40      45
10     Arg Asn Arg Pro Gly Ser Ile Val Gln Gly Val Cys Gly Cys Cys Tyr
      50      55      60
      Thr Cys Ala Ser Gln Gly Asn Glu Ser Cys Gly Gly Thr Phe Gly Ile
      65      70      75      80
      Tyr Gly Thr Cys Asp Arg Gly Leu Arg Cys Val Ile Arg Pro Pro Leu
      85      90      95
15     Asn Gly Asp Ser Leu Thr Glu Tyr Glu Ala Gly Val Cys Glu Asp Glu
      100      105      110
      Asn Trp Thr Asp Asp Gln Leu Leu Gly Phe Lys Pro Cys Asn Glu Asn
      115      120      125
      Leu Ile Ala Gly Cys Asn Ile Ile Asn Gly Lys Cys Glu Cys Asn Thr
      130      135      140
20     Ile Arg Thr Cys Ser Asn Pro Phe Glu Phe Pro Ser Gln Asp Met Cys
      145      150      155      160
      Leu Ser Ala Leu Lys Arg Ile Glu Glu Glu Lys Pro Asp Cys Ser Lys
      165      170      175
      Ala Arg Cys Glu Val Gln Phe Ser Pro Arg Cys Pro Glu Asp Ser Val
      180      185      190
25     Leu Ile Glu Gly Tyr Ala Pro Pro Gly Glu Cys Cys Pro Leu Pro Ser
      195      200      205
      Arg Cys Val Cys Asn Pro Ala Gly Cys Leu Arg Lys Val Cys Gln Pro
      210      215      220
      Gly Asn Leu Asn Ile Leu Val Ser Lys Ala Ser Gly Lys Pro Gly Glu
      225      230      235      240
30     Cys Cys Asp Leu Tyr Glu Cys Lys Pro Val Phe Gly Val Asp Cys Arg
      245      250      255
      Thr Val Glu Cys Pro Thr Val Gln Gln Thr Ala Cys Pro Pro Asp Ser
      260      265      270
      Tyr Glu Thr Gln Val Arg Leu Thr Ala Asp Gly Cys Cys Thr Leu Pro
      275      280      285
35     Thr Arg Cys Glu Cys Leu Ser Gly Leu Cys Gly Phe Pro Val Cys Glu
      290      295      300
      Val Gly Ser Thr Pro Arg Ile Val Ser Arg Gly Asp Gly Thr Pro Gly
      305      310      315      320
      Lys Cys Cys Asp Val Phe Glu Cys Val Asn Asp Thr Lys Pro Ala Cys
      325      330      335
40     Val Phe Asn Asn Val Glu Tyr Tyr Asp Gly Asp Met Phe Arg Met Asp
      340      345      350
      Asn Cys Arg Phe Cys Arg Cys Gln Gly Gly Val Ala Ile Cys Phe Thr
      355      360      365
      Ala Gln Cys Gly Glu Ile Asn Cys Glu Arg Tyr Tyr Val Pro Glu Gly
      370      375      380
45     Glu Cys Cys Pro Val Cys Glu Asp Pro Val Tyr Pro Phe Asn Asn Pro
      385      390      395      400
      Ala Gly Cys Tyr Ala Asn Gly Leu Ile Leu Ala His Gly Asp Arg Trp
      405      410      415
      Arg Glu Asp Asp Cys Thr Phe Cys Gln Cys Val Asn Gly Glu Arg His
      420      425      430
50     Cys Val Ala Thr Val Cys Gly Gln Thr Cys Thr Asn Pro Val Lys Val
      435      440      445
      Pro Gly Glu Cys Cys Pro Val Cys Glu Glu Pro Thr Ile Ile Thr Val
      450      455      460
      Asp Pro Pro Ala Cys Gly Glu Leu Ser Asn Cys Thr Leu Thr Arg Lys
      465      470      475      480
55     Asp Cys Ile Asn Gly Phe Lys Arg Asp His Asn Gly Cys Arg Thr Cys

```

EP 1 166 799 A1

					485					490					495	
	Gln	Cys	Ile	Asn	Thr	Gln	Glu	Leu	Cys	Ser	Glu	Arg	Lys	Gln	Gly	Cys
				500					505					510		
5	Thr	Leu	Asn	Cys	Pro	Phe	Gly	Phe	Leu	Thr	Asp	Ala	Gln	Asn	Cys	Glu
			515					520					525			
	Ile	Cys	Glu	Cys	Arg	Pro	Arg	Pro	Lys	Lys	Cys	Arg	Pro	Ile	Ile	Cys
		530					535				540					
	Asp	Lys	Tyr	Cys	Pro	Leu	Gly	Leu	Leu	Lys	Asn	Lys	His	Gly	Cys	Asp
	545					550				555						560
10	Ile	Cys	Arg	Cys	Lys	Lys	Cys	Pro	Glu	Leu	Ser	Cys	Ser	Lys	Ile	Cys
				565						570					575	
	Pro	Leu	Gly	Phe	Gln	Gln	Asp	Ser	His	Gly	Cys	Leu	Ile	Cys	Lys	Cys
				580					585					590		
	Arg	Glu	Ala	Ser	Ala	Ser	Ala	Gly	Pro	Pro	Ile	Leu	Ser	Gly	Thr	Cys
			595					600					605			
15	Leu	Thr	Val	Asp	Gly	His	His	Lys	Asn	Glu	Glu	Ser	Trp	His	Asp	
		610				615					620					
	Gly	Cys	Arg	Glu	Cys	Tyr	Cys	Leu	Asn	Gly	Arg	Glu	Met	Cys	Ala	Leu
	625					630				635					640	
	Ile	Thr	Cys	Pro	Val	Pro	Ala	Cys	Gly	Asn	Pro	Thr	Ile	His	Pro	Gly
				645						650				655		
20	Gln	Cys	Cys	Pro	Ser	Cys	Ala	Asp	Asp	Phe	Val	Val	Gln	Lys	Pro	Glu
				660				665						670		
	Leu	Ser	Thr	Pro	Ser	Ile	Cys	His	Ala	Pro	Gly	Gly	Glu	Tyr	Phe	Val
			675					680					685			
	Glu	Gly	Glu	Thr	Trp	Asn	Ile	Asp	Ser	Cys	Thr	Gln	Cys	Thr	Cys	His
		690				695					700					
25	Ser	Gly	Arg	Val	Leu	Cys	Glu	Thr	Glu	Val	Cys	Pro	Pro	Leu	Leu	Cys
	705				710					715					720	
	Gln	Asn	Pro	Ser	Arg	Thr	Gln	Asp	Ser	Cys	Cys	Pro	Gln	Cys	Thr	Asp
				725					730					735		
	Gln	Pro	Phe	Arg	Pro	Ser	Leu	Ser	Arg	Asn	Asn	Ser	Val	Pro	Asn	Tyr
			740					745					750			
30	Cys	Lys	Asn	Asp	Glu	Gly	Asp	Ile	Phe	Leu	Ala	Ala	Glu	Ser	Trp	Lys
			755				760						765			
	Pro	Asp	Val	Cys	Thr	Ser	Cys	Ile	Cys	Ile	Asp	Ser	Val	Ile	Ser	Cys
		770					775				780					
	Phe	Ser	Glu	Ser	Cys	Pro	Ser	Val	Ser	Cys	Glu	Arg	Pro	Val	Leu	Arg
	785					790				795						800
35	Lys	Gly	Gln	Cys	Cys	Pro	Tyr	Cys	Ile	Lys	Asp	Thr	Ile	Pro	Lys	Lys
				805						810					815	
	Val	Val	Cys	His	Phe	Ser	Gly	Lys	Ala	Tyr	Ala	Asp	Glu	Glu	Arg	Trp
				820					825					830		
	Asp	Leu	Asp	Ser	Cys	Thr	His	Cys	Tyr	Cys	Leu	Gln	Gly	Gln	Thr	Leu
			835					840					845			
40	Cys	Ser	Thr	Val	Ser	Cys	Pro	Pro	Leu	Pro	Cys	Val	Glu	Pro	Ile	Asn
		850					855					860				
	Val	Glu	Gly	Ser	Cys	Cys	Pro	Met	Cys	Pro	Glu	Met	Tyr	Val	Pro	Glu
	865					870				875					880	
	Pro	Thr	Asn	Ile	Pro	Ile	Glu	Lys	Thr	Asn	His	Arg	Gly	Glu	Val	Asp
				885						890					895	
45	Leu	Glu	Val	Pro	Leu	Trp	Pro	Thr	Pro	Ser	Glu	Asn	Asp	Ile	Val	His
				900					905					910		
	Leu	Pro	Arg	Asp	Met	Gly	His	Leu	Gln	Val	Asp	Tyr	Arg	Asp	Asn	Arg
		915					920						925			
	Leu	His	Pro	Ser	Glu	Asp	Ser	Ser	Leu	Asp	Ser	Ile	Ala	Ser	Val	Val
		930					935					940				
50	Val	Pro	Ile	Ile	Ile	Cys	Leu	Ser	Ile	Ile	Ile	Ala	Phe	Leu	Phe	Ile
	945					950					955				960	
	Asn	Gln	Lys	Lys	Gln	Trp	Ile	Pro	Leu	Leu	Cys	Trp	Tyr	Arg	Thr	Pro
				965						970					975	
	Thr	Lys	Pro	Ser	Ser	Leu	Asn	Asn	Gln	Leu	Val	Ser	Val	Asp	Cys	Lys
				980					985					990		
55	Lys	Gly	Thr	Arg	Val	Gln	Val	Asp	Ser	Ser	Gln	Arg	Met	Leu	Arg	Ile
			995					1000					1005			



EP 1 166 799 A1

Ala Glu Pro Asp Ala Arg Phe Ser Gly Phe Tyr Ser Met Gln Lys Gln  
1010 1015 1020  
Asn His Leu Gln Ala Asp Asn Phe Tyr Gln Thr Val  
1025 1030 1035

5

<210> 36  
<211> 716  
<212> DNA  
10 <213> homo sapiens

<400> 36

15 gcagtacctg gagtgcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60  
acccggggct cctgggccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120  
agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180  
ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240  
ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300  
ttgagggaaat ctctgatte tccttatatg acctcaaact gaccatacta aacagtgtag 360  
aagggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420  
20 gtcagtgtgg agtagacggg ttctccacc caggggtgac tcagggggat gatctgggtc 480  
ccattctggt cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540  
tctggttagt gtcgtaacct ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600  
cccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660  
gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

25 <210> 37  
<211> 395  
<212> DNA  
<213> homo sapiens

<400> 37

30 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60  
aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120  
tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180  
atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240  
gcccagtaaa accaaagtca gggtaaccaa tgtcatttta caaatgtta aaacctaat 300  
35 tgaggttcct tttttaaatt attttaaga ttacttaaca acattagaca gtgcaaaaaa 360  
agaagcaagg aaagcattct taattctacc atcct

<210> 38  
<211> 134  
<212> DNA  
40 <213> homo sapiens

<400> 38

45 ccctcgagcg gccgccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60  
aaccataaa gctgcctggc tttagcaac aggcctatca acaccatggt gagtctccat 120  
aagggaaccc gtgt

<210> 39  
<211> 644  
<212> DNA  
50 <213> homo sapiens

<400> 39

55 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60  
cagtggcgct tgagtgggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120  
gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180  
ggaatattgg tggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240  
gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaaggcc acagccaaga 300

EP 1 166 799 A1

5      ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360  
       aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420  
       ttcgaccggg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480  
       caagagggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540  
       tcaaaggcctt ctttggaata actggaaga aagcagttaa agcagtttct gtgggtctaa 600  
       gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat  
  
 10      <210> 40  
       <211> 657  
       <212> DNA  
       <213> homo sapiens  
  
       <400> 40  
  
 15      ctttttgttt gggttttcca atgtagatgt cttagtgaaa tgtgcagata tactttgttc 60  
       cttatatggt caccagtggt aattatggac aaatacatta aaacaagggt tcctggccca 120  
       gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180  
       tagccagtggt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240  
       acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300  
       agcaaaatga gaacattaaa aagactcatt caagtatgag tataaaggcg atggaaattc 360  
       tgggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420  
       ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480  
 20      aacagtcaat ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540  
       taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaaattag 600  
       atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac  
  
 25      <210> 41  
       <211> 1328  
       <212> DNA  
       <213> homo sapiens  
  
       <400> 41  
  
 30      acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgaagt 60  
       ctgggttagtt ttgttaggct cattatgggt agggctcgta agatgtatat aagaacctac 120  
       ctatcatgct gtatgtatca ctcatcccat ttctatgttc catgcatact cgggcatcat 180  
       gctaataatgt atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240  
       ggtaaaaaaa attccccaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300  
       atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360  
       acttccctta cagtgccgtg tctaccacta caaggactgt gcatctaagt aataattttt 420  
 35      taagattcac tatatgtgat agtatgatat gcatttattt aaaatgcatt agactctctt 480  
       ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540  
       gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600  
       tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660  
       actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaaatatt 720  
       aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780  
 40      ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840  
       tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900  
       attggattga catatggttt gccagcctat gggtttacag gcattgccca aacatttctt 960  
       tgagatctat atttataagc agccatggaa ttcctattat gggatgttgg caatcttaca 1020  
       ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080  
       gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttactc 1140  
 45      ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200  
       tggaaaataa aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260  
       ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320  
       tgaaaaaa  
  
 50      <210> 42  
       <211> 987  
       <212> DNA  
       <213> homo sapiens  
  
       <400> 42  
  
 55      aacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60

EP 1 166 799 A1

5      tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120  
       taacccccgg ctatcagtcg ggaatggttg caccctcctt gctgtaggat ggaagcagcc 180  
       atggagtggt agggagggcg aataagacac cctccacag agcttgcat catgggaagc 240  
       tggttctacc tcttcctggt tcctttgttt aaaggccttg ctgggagcct tccttttggg 300  
       tgtctttctc ttctccaacc aacagaaaag actgctcttc aaaggtggag ggtcttcattg 360  
       aaacacagct gccaggagcc caggcacagg gctgggggcc tggaaaaagg agggcacaca 420  
       ggaggaggga ggagctggtg gggagatgct ggctttacct aaggtctcga aacaaggagg 480  
       gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540  
       tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600  
 10      gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660  
       cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720  
       tgaggcttgg gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780  
       aatagtctac ggccatacca cctgaacgt gcctaattctc gtaagctaag cagggtcagg 840  
       cctggttagt acctggatgg ggagagtatg gaaaacatac ctgccgcag ttggagtgg 900  
       actctgtctt aacagtagcg tggcacacag aaggcactca gtaataactt gttgaataaa 960  
       tgaagtagcg atttgggtgtg aaaaaaa

15      <210> 43  
       <211> 956  
       <212> DNA  
       <213> homo sapiens

20      <400> 43

25      cggacggtgg ggcggacgcy tgggtgcagg agcagggcgg ctgccgactg ccccaaccaa 60  
       ggaaggagcc cctgagtcg cctgcgcctc catccatctg tccggccaga gccggcatcc 120  
       ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180  
       tcaggggatg ttacactggt gctcggaag ggaggggaa gggccgggga gggggcacgg 240  
       cagggctgtg gcagccacac gcagggcgcc agggcggcca gggacccaaa gcaggatgac 300  
       cacgcacctc cagccactg cctccccga atgcatttgg aaccaaaagtc taaactgagc 360  
       tcgcagcccc cgcgcctcc ctcgcctcc catcccgctt agcgctctgg acagatggac 420  
       gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480  
       gagattgctg gaaaccaagt caggccaggt gggcggacaa aaggggccagg tgcggcctgg 540  
       ggggaaacga tgctccgagg actggactgt ttttttcaca catcgctgcc gcagcggtgg 600  
 30      gaaggaaagg cagatgtaaa tgatgtgtt gtttacaggg tatattttg atacctcaa 660  
       tgaattaatc cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720  
       tttgatctct cttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780  
       tcgcaggacc aagggggcgg ggactgctgg ctcacgcccc gctgtgtcct cctccctc 840  
       ccttccttgg gcagaatgaa ttcatgctg attctgtggc cgccatctgc gcagggtgg 900  
       ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

35      <210> 44  
       <211> 536  
       <212> DNA  
       <213> homo sapiens

40      <400> 44

45      aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60  
       cccctagttt ctaaagtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120  
       agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180  
       ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240  
       tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300  
       cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaaat 360  
       atTTTTTcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420  
       ctggaaaaag tgggttatgc caccttttaa accctttctg gtaaatatta tggtagctaa 480  
       agggtggttt ccccggcacc tggacctgga caggtagggt tccgtggtta accagt

50      <210> 45  
       <211> 1630  
       <212> DNA  
       <213> homo sapiens

55      <400> 45

EP 1 166 799 A1

5 ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcaactggcc tgaccatccg 60  
 gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120  
 tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180  
 atcccctctg gagggaaagag gcaggaaaat tctccccggg tcctctgcat gctactttct 240  
 ccatacccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300  
 gtgatttccc ttaggcccag gacttggggc tccagctcat ctgttccttc tggggccatt 360  
 catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420  
 gactttacct gattgccttc agtttggggg tgcttattgg gaaagagaga gacaaagagt 480  
 tactttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540  
 10 gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600  
 attaggaagt cgggggtggg tgggtggtgg gggctagtgg gggttgaatt taggggccga 660  
 tgagcttggg tacgtgagca ggggtgtaag ttagggtctg cctgtatttc tgggtccctt 720  
 ggaaatgtct ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780  
 agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggg 840  
 gcccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttggtggc 900  
 15 tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960  
 gactttgttc gtagagcctt cttagaggtt agaataattag cttcaggatc agctgggggt 1020  
 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaagg 1080  
 tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagt 1140  
 aggtctggag gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200  
 aaagagtggc cttagagggc tccttgggccc tcagggaatgc tcctgctgct gtgaagatga 1260  
 20 gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320  
 ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380  
 tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat tcccagagg 1440  
 actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500  
 cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560  
 cctcttgcct cttgtagaat gcagctctgg ccctcaataa atgcttctg cattcatctg 1620  
 25 caaaaaaaaaa  
 <210> 46  
 <211> 169  
 <212> DNA  
 <213> homo sapiens  
 30 <400> 46  
 tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggctctga 60  
 taaaactggg ttatgatctt cagtctgatt ccagtgtctg ataactagat aacgtatgaa 120  
 ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaga cttagttaga  
 35 <210> 47  
 <211> 769  
 <212> DNA  
 <213> homo sapiens  
 40 <400> 47  
 tgcagggtcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtgga 60  
 atttgtcgct ttactttttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120  
 acataactcc agttcttacc atgagaacag catgggtgatc acgaaggatc ttcttgaaaa 180  
 aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataga 240  
 45 aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300  
 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360  
 cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420  
 ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480  
 catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatggtt 540  
 tattttgtaa taaaatcaaa ttcccatggt aaaccttcaa aaactttgca gaatgaggtt 600  
 50 ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660  
 cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720  
 ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc  
 <210> 48  
 <211> 2529  
 <212> DNA  
 55 <213> homo sapiens

&lt;400&gt; 48

```

5  tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
   gtgaaaatta gtgactgggt aaggtgtgcc actgtacata tcatcatattt ctgactgggg 120
   tcaggacctg gtcctagtcc acaaggggtg caggaggagg gtggaggcta agaacacaga 180
   aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtgggtga gcttgccgag 240
   ggatgggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
   gccttactta gtccttgcca gagggtgagt ggggacctac gaggttcaaa atcaaatggc 360
   atttggccag cctggcttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420
10  tgggctcact ccatttcatt gaagatcca aatgattcat tttcctaccc acaactttc 480
   attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
   actagtggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
   ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagt 660
   ggtgccacag gggcttcaaa atctatcagg cacactataa agctgggtgt tcttccctac 720
   caagtggatt cggcatatga accacctact caatacttta tattttgtct gttaaacaac 780
15  tgaactcttg tgttgacagg tacaaggagg aagagatggg gactgtgaag aggggagggc 840
   ttcctctatc ttcctcaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900
   ggaagccacg gggcttccca ccatttgttg gttattgctg ggggttagcca ggagcagtg 960
   ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttgggggtct 1020
   ccagaagagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
   aggtgaacag tcctacctgc ttgggtacct agtccctcaa taagattcag aggaagaagc 1140
20  ttatgaaact gaaaatcaaa tcaaggattt gggaagaata atttccctc gattccacag 1200
   gagggagagc cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
   acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctgggttt agcacacata 1320
   caaggagttt tcagggaaact ctatcaagcc atacaaaaat cagggtcaca tgtgggttcc 1380
   cccttctcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcag 1440
   gcagtggggc tgacctgaca aagccccagc tttcctgttg cagggtcttg gagaggatgc 1500
25  attcaagctt ctgcagccta ggggacaggg ctgcttgttc agttattact gcctcgagc 1560
   tccaaatccc accaaagtcc tgactccagg tcttctctaa tgcacagtag tcagtctcag 1620
   cttcggcagc attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
   agggagaaa gctgatggga acctgtgagt taagccacat gtctcaccag gaataattta 1740
   tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
   ccagagccaa taaaagatct ttgagctctc ggtgaattca cgaagtgacc ccagctttag 1860
30  ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
   gggggagtg gaggggaggg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
   ctctatctga ggagccccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
   tgaaaatttc cagaaatacc atttgggtga tcccttgtt tctgtaatat taaactcagg 2100
   tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
   gcagaactgg ctgaaacaag atttcatggt gtccccatg agagatgact caatgccaa 2220
35  gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactgggt 2280
   tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
   ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
   gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
   catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
   ggggtgtccc

```

&lt;210&gt; 49

&lt;211&gt; 1552

&lt;212&gt; DNA

&lt;213&gt; homo sapiens

&lt;400&gt; 49

```

5  tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
   ttcatatata tatatacata catatataaa ggaacaatt tgcaaattha cacacctgac 120
   aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
   ctagccaggc ccgttttcca tccctaagta ccattctctc atttggggcc ttctagggtt 240
10  gggggccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
   tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt ttacgtgat 360
   ccatcaagag ggctatggga gccaaagtga cacgggggat tgaggctaatt tcacctgaac 420
   tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttctcga 480
   gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggtctcg gctcactgca 540
   agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
55  taggtgccaa ccactacgcc tagctaattt ttttttgtat ttttagtaga gacagggttt 660

```

caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720  
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780  
 atgacaccag ttcttggtt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840  
 5 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggtgtctctc 900  
 cggagcggtt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtctctc 960  
 actttcagtgg tgcacctgga tgggtggaagc cagcctttgg ggcaggaaac cagctcagag 1020  
 aggctaccca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaaag 1080  
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140  
 ggatgagctt cactcaacgt ggagatggtg gtggactggt ccctgaaaag cgggccttgc 1200  
 agggccaagt gaggctcctca ggtcctaacc cagtggccct ctgaaagggg gtgtgcaggc 1260  
 10 gaggggagca ggaggcttct ctctagtccc tttggaggct ttggctgaga gaagagttag 1320  
 caggagagct ggaaatggtcc aggcaggga gggagctgaa gtgattcggg gctaatagct 1380  
 cagatcgatg tatttctctc cctggctctc cggagccctc ttgtcaccgc tgctgccttg 1440  
 caggaggccc atctcttctg ggagcttatc tgacttaact tcaactacaa gtctgctctt 1500  
 acgagaccgg gggtagcgtg atctcctgct tcctgagcg cctgcacggc ag  
  
 15 <210> 50  
 <211> 921  
 <212> DNA  
 <213> homo sapiens  
  
 <400> 50  
  
 20 ctgtgtgtccc agctactcag gaggctgagg cgggaggatt gcttgagccc aggagttgga 60  
 tgttgacgtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120  
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180  
 gctctgcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgagggttgg 240  
 25 tcccggggag cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300  
 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360  
 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatg ggcaagcatg 420  
 tgcctgctctg tgtgtgtgcg tgcccctccc ctgcagccgt cgggtgtatc tccctccagc 480  
 cccttcgcca ccttctgagc attgtctgtc cactgagac tgcccagaga cagcagagct 540  
 ccacgtgggtt ttaaggggag acctttccct ggacctgggg gtctcgcctg atctcatgac 600  
 cagggtgctaa atgacccgac atgcatcacc tgcccttcga tgaccaacct ccctgtcccc 660  
 30 gtcccgtga cctgcccccg tggcgtctca cggatgatgc tgctcctgac attgggtgtc 720  
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780  
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840  
 tactttgacc tcttgcttac aacccttccc ttgggtccga ggctggtagc tttgttctact 900  
 tcagatgggt gggggcggtt g  
  
 35 <210> 51  
 <211> 338  
 <212> DNA  
 <213> homo sapiens  
  
 <400> 51  
  
 40 atgatctatc tagatgcctt accgtaaaaat caaaacacaa aaccctactg actcattccc 60  
 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120  
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180  
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttctg 240  
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300  
 45 gtaagaaact ttctttcttg aattcttggg tctcttgg  
  
 <210> 52  
 <211> 1191  
 <212> DNA  
 <213> homo sapiens  
  
 50 <400> 52  
  
 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacaacat cgggggatgg 60  
 ctgtgtgttg ctagagcaga ggctgattaa aactcagtg tgttggctct ctgtgccact 120  
 cctggaaaat aatgaattgg gtaaggaaca gttaataaga aaatgtgcct tgctaactgt 180  
 55 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgcggttc 240

EP 1 166 799 A1

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

aaacttgatc gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300  
 tacatgtgtc tgtctggcct gatctgtgca tctgctcggg gacgtcctg acaagtccgg 360  
 aatttctcta tttctccact ggtgcaaaaga gcggatttct ccttgcttct cttctgtcac 420  
 ccccgctcct ctccccagg aggtcctctg atttatggta gctttggact tgcttccccg 480  
 tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540  
 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600  
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660  
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720  
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780  
 aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840  
 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaagagaaa gaaagagcag 900  
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacataacct 960  
 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaagctt 1020  
 tatatgccat ggaattaaa gttgaaaaag acttgaagac tggagaaaag acagtctctg 1080  
 cttccaatac ctctggccat cagatgactt taaaaggtag aggagtaaaa gtttaagatg 1140  
 atgggcaaaa gtccagtgtg ttcagtaaaag tgctaatac aagttggagg t

<210> 53  
 <211> 1200  
 <212> DNA  
 <213> homo sapiens

<400> 53

aacagggact ctcaacttat caaccccagg ctggagtcgg gtgcgcccac cctggctccc 60  
 tgcaacctcc gctctccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120  
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180  
 cgccttctgt ccaggccggc atcatatact ttaaatacatg ccagatgac ttttaatacct 240  
 aatacaatat atcagggttg tttaaaaata attgcttttt tattattttt gcatttttgc 300  
 accaacctta atgctatgta aatagttggt atactgttg ttaacaacag tatgacaatt 360  
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420  
 ttctcagtgt ttcaatttc tcttgggttg aatccatgga tgcaaaaacc acagatatga 480  
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540  
 atatgtagtg aaagtatttg tacagtggaa agagttagtg aaaacataaa catttggacc 600  
 tttcaagaaa ggtagcttg tgaaagtttt caccttcaaa ctatgtccca gtcagggtctc 660  
 tgctactaat tagctataat ctttgcaaaa attacatcac ctttgagtct cagttgcttc 720  
 acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780  
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaaat 840  
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900  
 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctattttatt 960  
 agagatgggg tctcactctg tccccagac tggagtacag tggcacatc atagctcact 1020  
 gctgcctcaa attcatgggc tcaagtgtac ctctgcctc tgccctccaga gtagctgcga 1080  
 ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140  
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

<210> 54  
 <211> 989  
 <212> DNA  
 <213> homo sapiens

<400> 54

aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga cattttatttt 60  
 tatgcctttc ttccatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120  
 gattcaatta gtccctgggc tggctgactg tgcaggagtc caggagcct ctacaaatgc 180  
 agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttccctca 240  
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaa 300  
 cgactgtgat agagggtgct acatgaacat tgctactgtc tttctttttt tttgagacag 360  
 gtttcgcttg tgcccaggct gagtgaatg cgtgatctca ctactgcaa ttcacacctc 420  
 aggttcaagc attctcctgc tcagcctcct agtagctggg ttacaggcac tgccacctg 480  
 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggctcagg ggtctcgaa 540  
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600  
 cgaccggcca ctactgtctt tctttgacct ttccagtttc gaagataaag aggaataaat 660  
 ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720  
 atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaagag 780

EP 1 166 799 A1

ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840  
 ttaatatatt tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900  
 tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtgc actggcgcaa 960  
 gcccggtcga ccgcaatctc tgccacccg

5 <210> 55  
 <211> 250  
 <212> DNA  
 <213> homo sapiens

10 <400> 55

catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60  
 gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120  
 agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180  
 aaagggcatt ctttaggaac tgcattctggt aacccacacc ttgatccaag agctagggaa 240  
 acttcagttg

15 <210> 56  
 <211> 2270  
 <212> DNA  
 <213> homo sapiens

20 <400> 56

gcgccccga gcagcgccc cgcctccgc gccttctccg ccgggacctc gagcgaaaga 60  
 ggcccgcgcg ccgcccagcc ctgcctccc tgcccaccgg gcacaccggg ccgccacccc 120  
 gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgctct cgctcgcccg 180  
 ctgcgcccg gctactcctg cgcgccacaa tgagctcccg catcgccagg gcgctcgcc 240  
 tagtcgtcac ccttctccac ttgaccaggc tggcgctctc cactgcccc gctgctgccc 300  
 actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctgcg 360  
 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420  
 accacaccaa ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480  
 gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaaacgggg 540  
 aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600  
 ttctctctgt tccccaaaga ctatctctcc ccaacttggg ctgtcccaac cctcggtcg 660  
 tcaaggttac cgggagtgcc tgccagagag ggtctctgta cgaggatagt atcaaggacc 720  
 ccattggagga ccaggacggc ctcttgggca aggagctggg attcgatgcc tccgaggtgg 780  
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggtccc 840  
 ctgttttttg aatggagcct cgcattcctat acaacccttt acaaggccag aaatgtattg 900  
 ttcaaaacaac ttcatggtcc cagtgtcaca agacctgtgg aactgggtatc tccacacgag 960  
 ttaccaatga caaccctgag tgccgccttg tgaaagaaac ccgatttgtt gaggtgcgcc 1020  
 cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080  
 aatcccccg accagtcagg tttacttacg ctggatgttt gagtgtgaag aaataccggc 1140  
 ccaagtactg cggttcctgc gtggacggcc gatgctgcac gcccagctg accaggactg 1200  
 tgaagatgcg gttccgctgc gaagatgggg agacattttc caagaacgtc atgatgatcc 1260  
 agtccctgca atgcaactac aactgccgc atgccaatga agcagcggtt cccttttaca 1320  
 ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380  
 cctagacaaa caaggagaga gagtgtcaga atcagaatca tggagaaaat gggcgggggg 1440  
 ggtgtgggtg atgggactca ttgtagaaag gaagccttg tcatctctga ggagcattaa 1500  
 ggtattttcga aactgccaag ggtgctggtg cggatggaca ctaatgcagc cagatttga 1560  
 gaatactttg cttcatagta ttggagcaca tgttactgct tcattttga gcttgtggag 1620  
 ttgatgactt tctgttttct gtttgtaaat tatttgctaa gcataatttc tctaggtttt 1680  
 tttccttttg gggttctaca gtcgtaaaag agataataag attagttgga cagtttaaag 1740  
 cttttattcg tcctttgaca aaagtaaag ggagggcatt ccatcccttc ctgaaggggg 1800  
 acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860  
 ggtgttttaa gactgaatgt tttatttatc aaaatgtagc ttttggggag ggaggggaaa 1920  
 tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980  
 tatggaatta accatttaat aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040  
 tattttttaga ggtgtcccaa agtcattagg aacaacctag ctcacgtact caattattca 2100  
 aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160  
 ttataccttc agtagagaaa agtctttgca tataaagtaa tgtttaaaaa acatgtattg 2220  
 aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

55 <210> 57



<211> 1636  
 <212> DNA  
 <213> homo sapiens

5

<400> 57

10

15

20

25

30

```

cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60
agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
tggtttgctt ggtctcaagg aactgcatc gtcaaactga tccccctggc gttggaggag 240
cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
agccccgggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtcccc 420
gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
agcttcacac ccagtggcag tttgattttg gtctccgcgt cacgggataa gactcttcgc 600
atctgggacc tgaataaaca cgttaaacag attcaagtgt tatcgggcca cctgcagtgg 660
gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
agcagtggtt tctcttgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840
gataccaaag tgattatgtg ggaccctac accggcgaaa ggtgaggtc actccaccac 900
acccagggtt accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
tggggccctg aactgaaaac tcccattgca tttgtctcta tgaccaatgg gctttgtctg 1080
acattttttc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
tggacagctc ctagggctct gtcctcactg aagcacttat gccgaaaagc ccttcgaagt 1200
ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
cctgtcaaag ggagtgtctg gaataatggg ccaaaccatc ggtcttgcat tgaaatagca 1380
tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
aagatgggtg aggggtggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
gacctgtgc tgcgtt

```

<210> 58  
 <211> 460  
 <212> DNA  
 <213> homo sapiens

35

<400> 58

40

```

ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgcagcaggg 180
ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggagct gagaccatcc 240
atgcccgagc agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aacccaacca 360
gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
ccgagctcga attcgtaatc atggtcatag ctgtttcctg

```

45

<210> 59  
 <211> 1049  
 <212> DNA  
 <213> homo sapiens

<400> 59

50

55

```

atctgatcaa gaatacctgc cctggctcact ctgcggatgt ttctgtccac ttgttcacat 60
tgaggaccaa gatatacttt tttacagagg cacttgttcg gtctaacaca gacacctcca 120
tgacgacatg ctggctcaca ttttgagctt ctgcagaagt cccccctcca gcctggacta 180
cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
gtcagtgctt gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
ggatctacaa ttttgtagag ttttccattg tgaagtctgg tcatactttt actgcttgat 360
aaaatgtaaa cttcacctag ttcactctct ccaaatccca agatgtgacc ggaaaagtag 420

```

```

cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgcaca 480
ggacttttgc ggagagtttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
aatctttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600
5 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
10 aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagtctctgca 1020
acttcaagaa agactctggc tgttctcaa

```

<210> 60

<211> 747

<212> DNA

15 <213> homo sapiens

<400> 60

```


tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
20 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
cttaaatata atgtatcata ccaaccctaa taaaccaagt acaaaaaata ttcatataaa 180
gttggttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt cctcctgtgg 420
25 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
ccctcgggca ggcaacggca gtggactcat ctgggtgatg gctgtagatg ctaacactgg 540
ccaattcaat gccacaccta ctggttacc tttgagggca tttctccaga cagaagcccc 600
ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgacgggc 720
30 cgcgaaattta gtagtaatag cggccgc

```

## Claims

- 35 1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 40 2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 45 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
- 50 4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 55 5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.


7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 5 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 10 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
  - a) compounds which inhibit receptor tyrosine kinase activity,
  - 15 b) compounds which inhibit ligand binding to receptors,
  - c) compounds which inhibit activation of intracellular signal pathways of the receptors,
  - d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
  - 20 e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
  - f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
- 25 11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of
  - g) compounds which inhibit receptor tyrosine kinase activity,
  - h) compounds which inhibit ligand binding to receptors,
  - 30 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
  - j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
  - k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
  - 35 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.
- 40 13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a
14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.
- 45 15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I




in which

r has the meaning of 0 to 2,  
n has the meaning of 0 to 2;

R<sub>3</sub> und R<sub>4</sub> a) each independently from each other have the meaning of lower alkyl,  
b) together form a bridge of general partial formula II,




wherein the binding is via the two terminal C- atoms,  
and  
m has the meaning of 0 to 4; or  
c) together form a bridge of partial formula III



wherein one or two of the ring members T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub>, T<sub>4</sub> has the meaning of nitrogen, and each others have the meaning of CH, and the binding is via the atoms T<sub>1</sub> and T<sub>4</sub>;  
G has the meaning of C<sub>1</sub>-C<sub>6</sub> - alkyl, C<sub>2</sub> - C<sub>6</sub> - alkylene or C<sub>2</sub> - C<sub>6</sub> - alkenylene; or C<sub>2</sub> - C<sub>6</sub> - alkylene or C<sub>3</sub> - C<sub>6</sub>-alkenylene, which are substituted with acyloxy or hydroxy; -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-) or imino (-NH-),  
A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,


Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
 R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or lower alkyl,  
 X has the meaning of imino, oxa or thia;  
 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted  
 or substituted cycloalkyl; and  
 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl,  
 hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, al-  
 kanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto,  
 sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-  
 sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfo-  
 nyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different  
 from each other, and wherein the bonds marked with an arrow are single or double bonds; or  
 an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a  
 salt thereof,

and/or a compound of general formula IV






in which

A has the meaning of group =NR<sup>2</sup>,  
 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR<sup>8</sup>,  
 Z has the meaning of the group =NR<sup>10</sup> or =N-, -N(R<sup>10</sup>)-(CH<sub>2</sub>)<sub>q</sub>-, branched or unbranched  
 C<sub>1-6</sub>-Alkyl or is the group



or A, Z and R<sup>1</sup> together form the group





m, n and o

q

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>

has the meaning of 0 - 3,

has the meaning of 1 - 6,

independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>, and/ or R<sub>a</sub> and/ or R<sub>b</sub> together with R<sub>c</sub> and or R<sub>d</sub> or R<sub>c</sub> together with R<sub>e</sub> and/ or R<sub>f</sub> form a bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,

X

has the meaning of group =NR<sup>9</sup> or =N-,

Y

has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,

P

has the meaning of integer 1-4,

R<sup>1</sup>

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R<sup>2</sup>


has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or form a bridge with up to 3 ring atoms with R<sub>a</sub>-R<sub>f</sub> together with Z or R<sub>1</sub>,

R<sup>3</sup>

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup>


independently from each other have the meaning of hydrogen, halogene or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R<sup>5</sup> and R<sup>6</sup> together form the group



R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup>

independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their isomers and salts,


and/ or a compound of general formula V




V,

in which


R<sup>1</sup> has the meaning of group



in which R<sup>5</sup> is chloro, bromo or the group -OCH<sub>3</sub>,



in which R<sup>7</sup> is -CH<sub>3</sub> or chloro,




in which R<sup>8</sup> is -CH<sub>3</sub>, fluoro,  
chloro or -CF<sub>3</sub>

in which R<sup>4</sup> is fluoro,  
chloro, bromo, -CF<sub>3</sub>,  
-N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or  
-CH<sub>2</sub>OH

in which R<sup>6</sup> is  
-CH<sub>3</sub> or chloro

R<sup>2</sup> has the meaning of pyridyl or the group



5

and

R<sup>3</sup> has the meaning of hydrogen or fluoro, as well as their isomers and salts.

10

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

20

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

25

19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

30

20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

35

21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

40

22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

45

50

55






Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 25 0214

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 98 35958 A (NOVARTIS ERFINDUNGEN VERWALTUN ; CIBA GEIGY AG (CH); TRAXLER PETER) 20 August 1998 (1998-08-20) * abstract * * page 1, paragraph 1 *	1-15, 21	A61K45/06
A	KOBLIZEK, THOMAS I. ET AL: "Angiopoietin-1 induces sprouting angiogenesis in vitro" CURR. BIOL. (1998), 8(9), 529-532 , XP000972727 * page 531, column 1, paragraph 2 *	1-21	
A	SCHLAEPPI, JEAN-MARC ET AL: "Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors." CANCER AND METASTASIS REVIEWS, (1999) VOL. 18, NO. 4, PP. 473-481. PRINT. , XP000972749 * page 477, column 2, paragraph 2 - page 478, column 1, paragraph 1 *	1-21	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims</p> <p>Claims searched completely</p> <p>Claims searched incompletely</p> <p>Claims not searched</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		12 January 2001	Leherte, C
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p> <p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>&amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/92 (P045207)



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number

EP 00 25 0214

Claim(s) searched completely:  
17-21

Claim(s) searched incompletely:  
1-16, 22

Reason for the limitation of the search:

Present claims 1-16, 22 relate to compounds defined by reference to desirable characteristics or properties, namely :

- " agents which modulates the biological function of one or several of the VEGF/VEGF receptor systems",
- " agents which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems",
- " agents which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems",
- " agents which are targeted to the endothelium",
- " agents which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems",
- " agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of the Angiopoietin/Tie receptor systems",
- " compounds which inhibit receptor tyrosine kinase activity",
- " compounds which inhibit ligand binding to receptors",
- " compounds which inhibit activation of intracellular signal pathways of the receptors",
- " compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor systems",
- " delivery systems, which target cytotoxic agents or coagulation-inducing agents to the endothelium",
- " delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis",
- " compounds of general formula I, IV or V".

The claims cover all compounds having those characteristics, properties or these general formulas, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the pharmaceutical compositions mentioned in the claims 17-21, with due regard to the therapeutic applications mentioned in claim 22.

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 25 0214

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-01-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9835958    A	20-08-1998	AU    6621898 A	08-09-1998
		BR    9807685 A	21-03-2000
		CN    1251097 T	19-04-2000
		CZ    9902853 A	17-11-1999
		EP    0970070 A	12-01-2000
		NO    993888 A	11-10-1999
		PL    335113 A	10-04-2000
		SK    109699 A	13-03-2000
		ZA    9801155 A	13-08-1998
-----			

EPO FORM 170459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82